HANNAH'S WILLBERRY WONDER PONY CHARITY

England & Wales · Charity number 1166416

Details

Status	Registered
Legal form	Charitable company
Company number	10089069
Registered	2016-04-07
Register	View on the Charity Commission register

Contact

Address	Manor Farm Hemington Radstock BA3 5XX
Phone	07774284373
Email	contact@willberrywonderpony.org
Website	www.willberrywonderpony.org

Activities

Objects: 4.1.1 To assist in the treatment and care of people suffering from bone cancer and other types of cancer and to relieve the charitable needs of people caring for them,4.1.2 To promote research into the causes, prevention and treatment of bone cancer and other types of cancer, and 4.1.3 To promote the health and wellbeing of: (a) people with a disability or serious illness; (b) people who are affected by the disability or serious illness of a close family member; or (c) people who are suffering from bereavement following the death of a close family member by providing or assisting in the provision of opportunities to ride or other equestrian related experiences.

Activities: We assist in the treatment and care of people suffering from bone cancer and other cancers and to relieve the charitable needs of people caring for them, to promote research into the causes, prevention and treatment of bone cancer and other cancers, and to promote health and wellbeing of people with a disability or serious illness by providing opportunities to ride or other equestrian experiences

Downloaded from opencharities.uk/ew/1166416

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations
- **What:** The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£155,090	£76,040	-	-
2024-03-31	£156,509	£72,879	-	-
2023-03-31	£103,613	£109,493	-	-
2022-03-31	£140,777	£134,309	-	-
2021-03-31	£96,899	£116,983	-	-

Trustees

Name	Role	Appointed
JUNE SANDRA CLOTHIER	Chair	2016-03-29
ALICE LERRYN GORING		2025-02-24
CHRISTOPHER TIMOTHY MILES TOULSON-CLARKE		2016-03-29
IAN ALAN DUNCAN PETERS		2016-03-29
James Francis		2016-10-10
MATTHEW PAUL CLARK		2025-02-24

Downloaded from opencharities.uk/ew/1166416

HANNAH'S WILLBERRY WONDER PONY CHARITY

England & Wales - Charity number 1166416

Accounts

Company registration number: 10089069

Charity registration number: 1166416

Hannah's Willberry Wonder Pony Charity

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2025

Hannah's Willberry Wonder Pony Charity

Contents

Trustees' Report	1 to 22
Reference and Administrative Details	21
Independent Examiner's Report	23 to 24
Statement of Financial Activities	25
Balance Sheet	26
Statement of Cash Flows	27
Notes to the Financial Statements	28 to 35

Hannah's Willberry Wonder Pony Charity

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements and auditors' report of the charitable company for the year ended 31 March 2025.

Objectives and activities

Our purpose

Hannah's Willberry Wonder Pony Charity seeks to provide a public benefit by:

- promoting research into the causes, prevention and treatment of bone cancer and other types of cancer;
- promoting the health and wellbeing of people with a disability or serious illness; or, people who are affected by the disability or serious illness of a close family member; or, people who are suffering from bereavement following the death of a close family member, by providing or assisting in the provision of opportunities to ride or enjoy other equestrian related experiences; and
- assisting in the treatment and care of people suffering from bone cancer and other types of cancer and to help people caring for them.

The Charity can provide:

- grants to organisations carrying out research into bone cancer, provided that the results of the research funded will be published. In the event that the Charity is not the sole funder of any research then the grant of funding will be subject to a condition that results of research will be published and available for general use;

- grants to organisations, individuals and their families to assist those affected by bone cancer and other types of cancer;

- an experience of an equestrian nature via our Willberry's Wishes team, making precious memories to treasure forever.

Background

Hannah Francis founded the charity, Hannah's Willberry Wonder Pony, in March 2016, having been diagnosed with osteosarcoma the year before at just 17 years old. She wanted to leave a legacy and help people like her who are affected by a serious illness and wanted the Charity to raise money to fulfil two principal objectives: to fund research into osteosarcoma ("Willberry's Research); and to provide equestrian experiences to seriously ill people and their families ("Willberry's Wishes"). The Charity went from strength to strength under Hannah's leadership and has continued to grow since her passing in August 2016, raising more than £2 million to date. The Charity has funded a number of significant research projects as Hannah so dearly wished; she fought so courageously and endured such archaic treatment that she never wanted anyone else to have to go through this. Hannah lived for her horses and whilst she was ill, she ticked many equine dreams off her bucket list, and this gave her the inspiration for "Willberry's Wishes". The Charity is granting Willberry's Wishes to seriously ill people in the hope that these experiences inspire others in the same way as they did Hannah, bringing a little happiness and hope during the darkest of times.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

We the Trustees are grateful to the thousands of people who have helped with donations, fundraising and spreading the word about Hannah's Willberry Wonder Pony Charity.

When necessary, the Charity engages the services of experts to assist with the running of the Charity but for the vast majority of the time it has been run by volunteers, including the Trustees, and we are very proud of everyone's efforts in keeping the cost of running the Charity to a minimum and thus ensuring maximum funds are available to apply to public benefit. However, the need for full time staff has been continually under review to ensure the Charity continues to run efficiently and maximises its public benefit and some changes in this respect have been made from 1 March 2025 and are reported in detail on page 19. That said, we are especially grateful to our volunteers for the financial protection they give us by giving many hours of their time, as well as opening their homes for meetings and providing storage space for our trading subsidiary's merchandise stock.

Our Activities During 2024/25 and Achievements to Date

We believe that the Charity has provided a public benefit in the following ways:

• In our ninth full year as a charity we have raised funds of £79,050 (previous year £83,630) on income of £155,090 (previous year £156,509). This was another successful year in terms of funds generation, with fundraising efforts delivering good growth in income. We are incredibly grateful for the fabulous fundraising efforts and donations from so many of our supporters. We also received generous donations from individuals, trusts and other charities. The money raised will help to provide funds to meet the Charity's objectives and provide public benefit in the years to come by helping fund bone cancer research and providing Willberry's Wishes.

• The trading subsidiary, which sells Willberry branded merchandise and donates all its profits to the Charity (£18,116 in 2024/25, previous year £24,438), has had another successful year. Demand remained steady for our Berry Ponies and for other items which were also sold at equestrian events including Badminton Horse Trials, where some riders still take to the cross-country course with their berry pony strapped to their backs, thus giving the Charity continued and valuable public profile. The portfolio of branded items offered is constantly reviewed to ensure that we keep our followers happy and achieve the best financial outcome.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

• During the year, we have provided a number of Willberry's Wishes to people who are fighting, or are affected by, serious illness. Spending during the year providing these experiences amounted to £4,485 which included:

* A lady was very poorly with breast cancer and her pony of 25 years sadly died, she wanted a portrait of her pony. We arranged for an artist to paint this, the lady was over joyed with the beautiful portrait of her beloved pony.
* A little girl with a terminal brain tumour wanted to have a pony party at home with her friends and family. We arranged for some ponies to go to her house, the morning was packed full of pony rides and pony pampering. A special pony cake was delivered and everyone received a special rosette. The little girl could not believe that she had ponies in her own back garden! A lovely lady came and took photos which we then created a photo album for the family, memories for everyone.
* A special girl who had battled cancer went to Badminton, where she had a lovely time. We also arranged for her to have a special VIP visit to the Badminton stables with a guided tour from Kitty King. She met many of the competitors and their famous horses.
* We helped another special girl with a terminal diagnosis. She owned a spritely horse called Patrick, full of energy making him a little too much for her to ride as she was so poorly. She adored her horse, so we wanted to include him in her wish, so we organised a photo shoot with her horse and family. A beautiful sunny day in Cornwall, creating some exquisite photos that we made into a book, making memories forever.
* For a tiny team, we created the largest wish - a pony party for the entire class, 38 children. A little girl with osteosarcoma who had missed so much school as she was in and out of hospital. She missed her friends and wanted to include them in her 'Willberry's Wish', so we travelled to Cornwall to hold a 'Pony Party' at her school. We arranged for a local riding school to join us; they brought some ponies and organised the rides for all the children. We split the class into four groups and they rotated around the activities, riding, dismounted gymkhana games, face painting, pin the tail on the donkey and decorating Willberry biscuits, a very busy afternoon! Then back to the classroom for a picnic, and to see the special cake we had made. Willberry had even brought party bags for all the children.

• We are extremely fortunate that many wonderful people in the equestrian community assist us in providing Wishes at no charge to the Charity. Since formation, many Wishes have been granted and all of these have been very well received by the recipients, although understandably not all permit publicity. We look forward to providing many more.

• In respect of medical research, we have in place an expert panel to assist the Trustees in selecting and analysing bone cancer research projects. The expert panel is headed by Dr Claire Clarkin, Associate Professor of Developmental Biology, University of Southampton, and she is very ably assisted by Dr Alice Goring, who completed a PhD related to the study of the role of blood vessels in bone diseases, and they both provide critical assistance to the Charity in managing the medical research investment process. We have continued to meet a number of clinical and academic specialists in the field of osteosarcoma research and have made significant progress in increasing the profile of the Charity in the academic and scientific communities, including advertising for PhD studentships with major universities.

Trustees' Report

• In total to date, we have identified and committed to twelve research projects from leading English Universities that we are supporting, with a combined value of up to £1,155,480, of which £45,316 was spent in the financial year. We are confident that in the coming years we will identify projects from other institutions that will assist in the identification of the causes, prevention and treatment of bone cancer and other types of cancer. These efforts will be significantly enhanced by last year's announcement that the Charity will be working together with The Bone Cancer Research Trust to offer funding of up to £250,000 (£125,000 funded by each charity) to support projects focused on improving outcomes for osteosarcoma patients.

The lead time for identifying, reviewing, approving and funding research projects remains up to 2 years. The Trustees are very conscious of the need to select prospective research projects carefully and to ensure the Charity's money is invested in a considered and appropriate way.

Our Strategy Going Forwards

• The Trustees continue to review the strategy of the Charity to ensure that it provides public benefit and has the ability to meet its objectives. The Trustees are hopeful that income generated in 2025/26 will meet our target of £100,000 and this, together with our strong reserves, will enable us to carry out the Charity's objectives in future years.

FUNDING RESEARCH PROJECTS

• As mentioned above, the Charity has entered into agreements to fund twelve research projects since the charity's inception. It remains shocking to note that chemotherapy treatment for osteosarcoma has changed little in the past 30 years and has a limited success rate. The treatment is barbaric and causes suffering and horrific side effects. New ways to fight this devastating disease are urgently needed.

The projects that we have funded, or are currently funding, are listed below:

COMPLETED RESEARCH PROJECTS

• The first is a fully funded post doctoral position and a part funded PhD student with the renowned Department of Oncology and Metabolism at Sheffield University with a total cost of £233,412. The project ran from 2019 to 2023 and can be summarised as follows:

Project Title: Can we identify new drugs for the treatment of osteosarcoma? and finding out why existing ones don't work

Key people: Professor Ali Gartland, Professor Dominique Heymann and Luke Tattersall and Victoria Tippett.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

BACKGROUND TO THE RESEARCH PROJECT

Osteosarcoma is the most common type of primary bone cancer affecting children and adolescents, it is a rare and often fatal disease. Historically, the overall 5-year survival rates for osteosarcoma were dire at below 20% with surgical intervention alone. The introduction of the addition of chemotherapy treatment after surgery in the 1970s radically increased rates to 50%. Since then, and the introduction of chemotherapy before surgery, the survival rate further increased to 60%. However, there has been no real advances in treatment options and the survival rates have remained poor. The 5-year survival rate is reported to be 53% for patients under 40, versus 22 % for those above. The rate is even worse for patients who present with metastatic disease at less than 30% and this has actually declined every decade, with no significant change in the survival when comparing the 21st Century figures to those from the 1970s.

Current treatments for osteosarcoma are also brutal and rely on classical chemotherapy drugs which have significant side effects due to the fact that they also kill non-cancerous cells and patients often become resistant to the therapy, meaning that they no longer work and further limiting their treatment options. This project aimed to find new kinder drugs that will work in osteosarcoma, even when they become resistant to the first line therapy.

KEY RESULTS

The Gartland lab has tested 4320 compounds from a "drug library", which includes many drugs and natural compounds that have already been shown to be harmless in people, for their effect at reducing the growth of osteosarcoma cells. Their extensive investigations using osteosarcoma cell lines in the laboratory have identified 5 compounds that are highly potent requiring low doses to reduce osteosarcoma cell growth. These drugs also reduced the ability of the osteosarcoma cells to move suggesting they may be able to prevent osteosarcoma spreading (metastasising) to other parts of the body.

The team also tested these drugs against osteosarcoma cells that they had made resistant to conventional doxorubicin chemotherapy and they were able to kill these cells too. In addition to these findings specifically in osteosarcoma, these drugs have been shown to have effects in other cancers.

They are now trying to get more evidence that these new drugs work so we can take them forward to being used in patients. The Gartland lab also used the chemoresistant cells they developed to investigate the way in which the osteosarcoma cells stop responding to the first line chemotherapy. Excitingly they have found new signalling pathways and potential drug targets that are involved in the cells becoming chemoresistant and now want to investigate these further as potential new treatment options for osteosarcoma.

Other outputs, knowledge and Future Steps

Publications:

The Gartland lab is currently refraining from publishing the full results from the studies of Dr Luke Tattersall until successful IP has been filed for; protecting the drug compounds, and increasing translatability into patients. The lab is trying to further validate the hits from the screening to get the pre-clinical evidence to take the hits forward to clinical use in patients. They are also trying to modify the drugs to target them specifically to bone and so reduce any potential side effects.

Trustees' Report

V.L. Tippett, L. Tattersall, K.M. Shah, Ab Latif, N.B, M.A. Lawson, A. Gartland. "The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review" Oncogene 2022

Presentations:

Oral Presentation at the first HWWPC research symposium, London, UK, "Can we find new effective treatments for osteosarcoma?" L. Tattersall, V.L Tippett, A. Higginbottom, A.Gartland

Poster Presentation at the Bone Research Society Annual Meeting, Liverpool, UK, "Establishment and characterisation of a human osteosarcoma metastatic cell line derived from a patient's lung for future preclinical use" L. Tattersall, V.L Tippett, J.K. Rantala, A. Higginbottom, A.Gartland.

Snap Oral Presentation at the 12th Annual Mellanby Centre Research day, Sheffield UK, "Establishment and characterisation of a human osteosarcoma metastatic cell line derived from a patient's lung for future preclinical use" L. Tattersall, V.L Tippett, J.K. Rantala, A. Higginbottom, A.Gartland.

Oral Presentation at the first PRESTO meeting, Ferrara, Italy. "The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties" L. Tattersall, K.M. Shah, D.L. Lath, A. Singh, J.M. Down, E. De Marchi, A.Williamson, F.Di.Virgilio, D. Heymann, E.Adinolfi, W.D. Fraser, D. Green, M.A. Lawson A.Gartland.

Oral Presentation at the Bone Cancer Research Trust Annual Conference (North) Leeds UK. "Can we find new effective treatments for osteosarcoma?" L. Tattersall, V.L Tippett, A. Higginbottom, A.Gartland

Snap Oral Presentation at the 11th Annual Mellanby Centre Research day, Sheffield UK, "Can we find new effective treatments for osteosarcoma?" L. Tattersall, V.L Tippett, A. Higginbottom, A.Gartland

Poster Presentation at the BSG annual conference Liverpool UK, "Can we find new effective treatments for osteosarcoma?" L. Tattersall, V.L Tippett, A. Higginbottom, A.Gartland

Oral Presentation at the 10 year UK Purine club anniversary conference, Sheffield UK, P2X7RB increases ectopic bone disease and lung metastasis in vivo L. Tattersall, K.M. Shah, D. Lath, J. Down, E. De Marchi, A. Williamson, F. Di Virgilio, E. Adinolfi, M.A. Lawson, A. Gartland.

Oral Presentation at the 9th Annual Mellanby Centre Research day, Sheffield UK, Effects of P2X7RB expression on MNNG-HOS osteosarcoma cells in vitro L. Tattersall, E. De Marchi, A. Williamson, F. Di Virgilio, M.A. Lawson, E. Adinolfi, A. Gartland

Poster Presentation at the BACR tumour microenvironment meeting, Nottingham UK P2X7RB increases ectopic bone disease and lung metastasis in vivo in osteosarcoma Tattersall. L, Down. J, Lath. D, De Marchi. E, Williamson. A, Di Virgilio. F, Adinolfi. E, Lawson. M.A, Gartland.

• The Charity has also part-funded a PhD student at the University of Manchester with a total cost of £51,057.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Project Title: Understanding how ERK5 controls osteosarcoma development and response to treatment.

Key people: Professor Katie Finegan, Kaye Williams, Adam McMahon, Alex Dzhoneva

BACKGROUND TO THE RESEARCH PROJECT

There is evidence from current research work undertaken in this lab that a protein called ERK5 can promote the progression of osteosarcoma. Clinical studies have also revealed a strong link between ERK5 signalling and outcomes for osteosarcoma patients. A recent study of samples from osteosarcoma patients showed that high levels of ERK5 correlated with disease progression (87% of patients), resistance to chemotherapy (53% of patients), and was detected in 70% of metastases, where it correlated with decreased overall survival.

ERK5 is a protein and sends many messages to other proteins, which then tell the cell what to do. Cells responding to the signal are not only tumour cells, but also cells that belong to the body's immune system, which in cancer, are hijacked to aid cancer progression. The team have initial evidence that removing ERK5 interrupts the signals or "conversation" between the immune cells and the tumour cells. A tumour cells "conversation" with the immune system is essential for both tumour growth and spread to other parts of the body. When genetic approaches to remove ERK5 from osteosarcoma cells growing in mice are used, this stops spread of the osteosarcoma cells to the lung. However, although it is known that eliminating ERK5 from the cells has significant impact on osteosarcoma progression, it is not known exactly how this happens. Understanding the "how" is pivotal to understanding the best way to target this pathway and inform design of drugs acting against ERK5 signalling for future patient use.

KEY RESULTS

• Blocking ERK5 either by the Finegan lab's genetic approach or by their new patented drug stops osteosarcoma cells from being able to spread.

• Blocking ERK5 (drug/genetic approach) enabled the lab to use a lower dose of chemotherapy to get the same effect. This means, in the future, the drug could be used to lower chemotherapy doses and therefore enable kinder treatment plans for patients.

• Blocking ERK5 (drug/genetic approach) is a possible new immunotherapy for osteosarcoma. The Finegan lab found that their drug can make the immune system more able to attack osteosarcoma tumours and also that it may be able to make current on-the-shelf immunotherapy more effective.

• The Finegan lab analysed patient tumour samples and this suggested that we can use ERK5 levels in patient samples as a way to identify patients that might be at higher risk of their cancer spreading.

• They have also found that most osteosarcoma patients tumours (~80%), but especially those patients tumours whose osteosarcoma had spread or had gone on to spread, had high ERK5 in them. Due to having lots of ERK5, these 80% of osteosarcoma patients would be very likely to benefit from our drugs that block ERK5.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Outputs

This project has allowed the lab to secure onward funding from Sarcoma UK and LifeARc to progress their drugs further towards use in patients and to develop their work on ERK5 levels in patient tumours. This means that they can use this clinically to identify high risk patients early on and therefore offer the best opportunities for treatment.

• The charity has also funded two part-funded PhD projects at the University of Southampton, with a combined funding of £102,449 over 3 years each between 2019 and 2023.

First Project Title: Developing a 3-dimensional multicellular model of human osteosarcoma

Key People: Dr Janos Kanzler, Professor Steve Beers, Professor Juliet Gray, Hannah Smith

BACKGROUND TO THE RESEARCH PROJECT

The most common bone cancer in young people is osteosarcoma. It is an aggressive cancer and unfortunately treatment hasn't progressed much in 40 years. This team at Southampton have created a laboratory model of osteosarcoma to try and better understand how this disease arises from normal bone cells and to test potential new therapies to prevent the growth of this cancer.

The origin of osteosarcoma cells in bone is still unknown, and this lack of understanding prevents early detection of this disease. Bone grows from specialised cells located in the bone marrow (the soft, jelly-like tissue found in the centre of most bones). In Hannah's PhD project, the team were interested to see if there were differences between the cells of the bone marrow from distinct locations of the long thigh bone and whether these differences might impact their ability to initiate disease.

To do this, they collected and grew these specialised bone marrow cells from different regions of human bones (these were called red and yellow bone marrow) where osteosarcoma cancers tend to develop. They then looked at the ability of these cells to change into three types of cells, osteoblasts which make bone, adipocytes which make fat and chondrocytes which make cartilage, all of which are critical in shaping, growing, and repairing our skeleton particularly at a youthful age. The team compared the characteristics of these cells with two known osteosarcoma cells (called Saos-2 and MG63). From Hannah's studies, she found that bone marrow specialised cells changed differently when stimulated depending on the region of the bone they came from. Improved understanding of the origin and the bone environment where these osteosarcoma cells develop could allow for earlier detection and treatment of the disease to improve the patients overall outcome.

KEY RESULTS

Why and how osteosarcoma cells start growing is still unknown, and this lack of understanding prevents early detection of this disease. Bone grows from specialised cells located in the bone marrow (The soft, jelly-like tissue found in the centre of most bones).

During Hannah's PhD, the team was interested to see if there were differences between the bone marrow cells from distinct locations of the femur which might impact their ability to initiate disease. They collected and grew these specialised bone marrow cells from two different regions (called red and yellow bone marrow) and found that there were big differences in how they changed into cells which make bone, fat, and cartilage.

They also looked at two types of osteosarcoma cancer cells and how similar they were to the bone marrow cells, with one called Saos-2 showing a similar ability to form bone like the bone marrow cells.

After incubating the bone cylinders they were successfully able to look at whether there was bone growth or loss, as well as changes in their features/traits. They identified that the cells stayed alive and were interacting in this model to recreate the human tumour.

Finally, the drug mifamurtide was tested on the bone model, and it was found that it resulted in a lower bone volume and changes in the model's characteristics, which will help in understanding why not all patients respond to mifamurtide.

Other outputs, knowledge and Future Steps

Publications:

*Smith, H. L., Beers, S. A., Kanczler, J. M., & Gray, J. C. Developing a 3D model of osteosarcoma to investigate cancer mechanisms and evaluate treatments. Submitted for publication Dec 2023 and under revision.

*Smith, H. L., Gray, J. C., Beers, S. A., & Kanczler, J. M. (2023). Tri-Lineage Differentiation Potential of Osteosarcoma Cell Lines and Human Bone Marrow Stromal Cells from Different Anatomical Locations. Int J Mol Sci, 24(4). https://doi.org/10.3390/ijms24043667

*Smith, H. L., Beers, S. A., Gray, J. C., & Kanczler, J. M. (2020). The Role of Pre-Clinical 3-Dimensional Models of Osteosarcoma. Int J Mol Sci, 21(15). https://doi.org/10.3390/ijms21155499

*Smith, H. L., Kanczler, J. M., Gray, J. C., & Beers, S. A. Monocyte Derived Macrophages: Peripheral Blood vs Bone Marrow. In final preparation for submission. Estimated End of Feb 2024.

Presentations:

2023 - Hannah's Willberry Wonder Pony Charity Symposium - Oral presentation
2022 - Centre for Human Development, Stem Cells and Regeneration conference Oral presentation
2020 - Bone Research Society: Osteosarcoma cells modulate skeletal stromal cell phenotype- site specific interactions. - Poster presentation
2020 - Cancer Research Club -Oral Presentation
2019 - 11th Annual Cancer Sciences Unit Conference - Poster Presentation

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Second Project Title: Harnessing Label-Free, Second Harmonic Generation Microscopy for Research and Diagnosis of Osteosarcoma

Key people: Belle Creith, Dr Claire Clarkin, Professor Sumeet Mahajan, Professor Richard Oreffo and University of Southampton

BACKGROUND TO THE RESEARCH PROJECT

This research project aims to introduce a new technology for the diagnosis and examination of osteosarcoma tumours. Current diagnosis of osteosarcoma is a very time-consuming process involving a number of imaging techniques and a confirmative biopsy.

Cutting-edge laser microscopes that allow the imaging of biological samples in a non-invasive manner are being widely explored in the field of cancer research as they do not require the use of any special dyes of labels.

This research project utilises one such laser microscope - known as second harmonic generation microscopy - being used as a new method for the diagnosis of osteosarcoma by examining abnormal collagen - a protein in our bones which is thought to be changed drastically within bone tumours.

KEY RESULTS

During this research project, the team developed an optimised imaging and analysis methodology that allowed accurate examination of collagen in human bone and osteosarcoma biopsies. Their findings provide proof-of-concept for osteosarcoma diagnosis by identifying abnormally short collagen fibres within osteosarcoma tumours compared to healthy bone. They also identified that these changes to collagen length become more pronounced with progression of osteosarcoma. Furthermore, the Southampton team discovered that the collagen of osteosarcoma tumours also shows some differences from the collagen in other bone cancers. Together, these results demonstrate the diagnostic ability of SHG microscopes by identifying diseased collagen. This could help with both diagnosis of the disease as well as prediction of osteosarcoma progression and response to treatment. Moreover, their findings also highlight diseased collagen as a biological molecule that may be targeted in future osteosarcoma treatment.

Other Outputs & Knowledge and Future Steps

Creith B, Johnson PB, Harrison J, Oreffo ROC, Mahajan S and Clarkin CE (2021). Prospects of multi-modal non-linear microscopy for research and diagnosis of osteosarcoma. Accepted for oral presentation. Bone Research Society Annual Meeting (virtual program), 28-30 June.

Creith B, Johnson PB, Harrison J, Oreffo ROC, Mahajan S and Clarkin CE (2022). Characterisation of Diagnostic Collagen Phenotypes in Human Osteosarcoma Biopsies Using Second Harmonic Generation Imaging. Accepted for poster presentation. Bone Research Society Annual Meeting, Manchester, 6-8 July.

Creith B, Johnson PB, Harrison J, Oreffo ROC, Mahajan S and Clarkin CE (2022). Disclosing Diagnostic Collagen Phenotypes in Osteosarcoma Biopsies with Second Harmonic Generation Imaging. Accepted for oral presentation. Gordon Research Seminar on Musculoskeletal Biological and Bioengineering, New Hampshire, USA, 6-7 August.

Creith B, Johnson PB, Harrison J, Oreffo ROC, Mahajan S and Clarkin CE (2022). Disclosing Diagnostic Collagen Phenotypes in Osteosarcoma Biopsies with Second Harmonic Generation Imaging. Accepted for poster presentation. Gordon Research Conference on Musculoskeletal Biological and Bioengineering, New Hampshire, USA, 7-12 August.

Creith B, Johnson PB, Harrison J, Oreffo ROC, Mahajan S and Clarkin CE (2022). Prospects of Label-Free Microscopy for Research and Diagnosis of Osteosarcoma. Invited for Talk. North Bone Cancer Research Trust Conference, Leeds, UK, 14-15 October.

Future steps: -

In parallel with our PhD funding Southampton was successful in obtaining further funding from Children with Cancer UK in collaboration with Janos Kanczler, University of Southampton on a project entitled Developing 3-dimensional multicellular models of osteosarcoma which was undertaken by Dr Aikta Sharma

Background : OS has been shown to be very sensitive to its surroundings and particularly that of circulating immune cells called macrophages. Macrophages protect the body by locating and "eating" particles, such as cancer cells, bacteria, viruses, fungi, and parasites. The presence of macrophages in OS has been reported to be associated with increased patient survival and has led to a targeted drug treatment called mifamurtide, a macrophage activator. However, recent evidence has questioned the benefit of this treatment approach in all patients. We urgently need to understand the microenvironment of OS and investigate how these macrophages can influence the clinical outcome of young OS patients. In this project, Dr Claire Clarkin and her team will develop a live 3D multicellular model of OS by combining human bone pieces, OS cells and immune cells, which will be kept alive and grown together inside a developing chicken egg. This sophisticated model of OS will better replicate the complex tumour microenvironment than existing models and will be used to assess the mechanisms underlying specific drugs, like mifamurtide, in killing OS cells. The research team will then use a powerful imaging technique called Raman Spectroscopy to identify any unique disease signatures. Identification of such signatures could act as an indicator for OS to improve diagnosis and will provide greater understanding into the role of immune cells in the progression of OS. This study will assess the potential for macrophage activation to be used in the treatment of OS and will allow drugs to be screened very rapidly to assess their effectiveness. The research team will identify and characterise unique OS cell signatures which could be used as indicators for the disease and could improve the speed of diagnosis.

Findings have demonstrated the utility of Raman spectroscopy in the characterisation of matrix signatures of osteosarcoma. The team have performed in-depth in vitro characterisation of low-to-high grade human osteosarcoma cell lines and validated the attained spectral signatures with biochemical assays which have enabled the deduction of cellular metastatic and differentiation capacities directly from extracellular matrix signatures. The project team's approaches can be used a platform for rapid screening of novel therapies for osteosarcoma treatments ahead of administration to larger preclinical models. The Clarkin lab's future funding strategy will utilise the methodologies developed herein to form the basis of a larger grant application (Medical Research Council, Cancer Research UK, Bone Cancer Research Trust) with focus on improving osteosarcoma diagnosis and treatment using multidisciplinary approaches.

Outputs:

Hornsey T, Sharma A, Michels L, Kerns J , Clarkin CE (2024). Machine Learning predicts unique extracellular matrix characteristics between osteosarcoma cell phenotypes. Submitted for oral and poster presentation at the European Calcified Tissue Congress, Marseille, France, May 2024.

Trustees' Report

Sharma A, Oreffo ROC, Mahajan S, Beers S, Kanczler J and Clarkin CE (2024). Raman spectroscopy reveals the association between nanomolecular matrix signatures with pro-angiogenic potential in osteosarcoma. Accepted for poster presentation at the Bone Cancer Research Trust Meeting: Advancing diagnosis of bone and soft tissue sarcomas, Leeds, UK, January 2024.

Sharma A, Oreffo ROC, Mahajan S, Beers S, Kanczler J and Clarkin CE (2023). Characterisation of osteosarcoma matrix signatures reveals nanoscale molecular composition is linked to pro-angiogenic potential. Accepted for oral and poster presentation at the Bone Research Society Annual Meeting and European Calcified Tissue Society Congress 2023, Liverpool, UK, April 2023.

Sharma A, Oreffo ROC, Mahajan S, Beers S, Kanczler J & Clarkin CE (2022). Nanoscale characterisation of osteosarcoma cell matrix signatures link to pro-angiogenic potential. Accepted for poster presentation at the Gordon Research Seminar and Conference on Musculoskeletal Biology and Bioengineering: Multi-scale Approaches to Understanding Musculoskeletal Tissues, New Hampshire, USA, August 2022.

• The Charity has also part-funded two PhD projects at the University of Middlesex with a combined projected cost of £204,325 between 2021 and 2028

First Project Title: Delineating the metastatic process: the role of bone cells, the cell environment and autophagy

Key people: Dr Helen Robert, Dr Scott Roberts and Daniela Paternina Martinez

BACKGROUND TO THE RESEARCH PROJECT

Metastatic disease is one of the major factors affecting osteosarcoma (OS) prognosis. Survival rate of patients with metastasis is 20% to 30% compared to up to 80% in non-metastatic patients. This project aims to identify how osteosarcoma cells spread to other tissues such as the lungs. Recent evidence shows that loss of a osteoclasts ((OCs); cells that break down bone) in the bone microenvironment is associated with lung metastasis.

KEY RESULTS

Due to the absence of innovative treatments for osteosarcoma (OS) since the advances in chemotherapy treatment in the early 1980s and the stagnant survival rates for patients with metastatic OS, there is a pressing demand for enhanced therapeutic approaches.

The Roberts lab have established a model for osteosarcoma initiation and metastasis, alongside the identification of key targets through sequencing that may be able to stop osteosarcoma in its tracks.

Other Outputs & Knowledge and Future Steps

Presentations:

Paternina Martinez, D., Roberts, S. and Roberts, H.C. (2022). Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Journal of Bone and Mineral Research Plus.

Trustees' Report

Paternina Martinez, D., Roberts, S.J and Roberts, H.C (2022). Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis. Research Students' Summer Conference. Middlesex University, London, UK June 2022.

Paternina Martinez, D., Roberts, S.J and Roberts, H.C (2023.) Osteoclasts and mesenchymal stromal cells release factors that modulate migratory body formation in highly metastatic osteosarcoma cells. Research Students' Summer Conference. Middlesex University, London, UK July 2023.

- Oral presentation at the Skeletal Biology Group Research Seminar - Presentation titled "Delineating the metastatic process in osteosarcoma: the role of bone cells, the cell environment and autophagy". Royal Veterinary College - February 2022, London.

- Poster presentation and poster pitch of abstract entitled "Migratory bodies express markers of tumour initiating cells and may represent an early stage of osteosarcoma sarcosphere initiation and metastasis" Bone Research Society Annual Meeting -July 2022, Manchester.

- Oral presentation titled "Bone cells modulate migratory behaviour of osteosarcoma: implications for metastasis" Bloomsbury Centre for Skeletal Research Meeting - June 2023, London.

CURRENT RESEARCH PROJECTS

The second follow on project with Middlesex is titled: **Suppress-OS: Targeting Osteoclast-Tumour Interactions to Suppress Osteosarcoma Metastasis**

Key people Dr Helen Roberts, Dr Song Wen

BACKGROUND TO THE RESEARCH PROJECT

Osteosarcoma, a form of bone cancer, becomes more challenging when it spreads, reducing the chance of survival. The Robert's lab hypothesise that OS establishes itself in bones by interacting with osteoclasts, specialised cells responsible for breaking down bone tissue. Disrupting this interaction allows osteosarcoma to spread to the lungs.

In Daniella's PhD project, the Roberts lab identified 'Migratory Bodies' (MBs) as a valuable laboratory model for studying the spread of osteosarcoma. Osteoclast factors slow down MBs, but the drug zoledronic acid (used to treat osteoporosis) can counteract this effect.

The team now look to explore this further by using genetic engineering to unravel how osteosarcoma spreads, with a particular focus on potential treatment targets STAT3 and MMP9.

Additionally, the team plan to examine osteosarcoma metabolism to enhance their understanding of metastasis. This research holds promise for refining osteosarcoma treatment strategies, incorporating insights into osteoclast interactions, with the ultimate goal of improving outcomes for patients.

Trustees' Report

PRELIMINARY DATA

This project is starting soon and marks our first follow-on funding project, where the teams behind our previous successfully funded projects were invited to apply for funding to ensure that the most successful of these projects remain supported and continue to grow.

• The Charity has also part-funded a PhD project at Kings College London with a project cost of £87,576 between 2022 and October 2025

Project Title: Drug repurposing targeting Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis

Key people: Professor Agamemnon Grigoriadis, Dr James N Arnold, Michael Dack

BACKGROUND TO THE RESEARCH PROJECT

The project focuses on understanding and preventing the growth of cancer cells in osteosarcoma patients, as well as looking to stop the spread of cancer around the body. The ability of osteosarcoma to metastasise or spread to different sites is what makes it so aggressive and therefore focusing the research on this is really important. Michael is looking at repurposing a pre-existing drug, which is currently used to treat neonatal jaundice, to block the action of HO-1. HO-1 is a factor which is produced by osteosarcoma patients and prevents the activation of the immune system. By 'kick-starting' the immune system into action, the project will assess if the chemotherapy drugs are able to fight the cancer and stop it from moving to other areas of the body.

KEY RESULTS

Michael is now in his second year of his PhD and has been busy making progress on his project. Using a technique called Flow cytometry, Michael has been able to identify the key cell types within the lung that could be helping osteosarcoma spread to this site. Armed with this finding, Michael is now delving deeper into the mechanism of how these cells are helping the spread and how might the drug, SnMP, be working to reactivate good immune cells to prevent osteosarcoma metastasis.

To share his research to potential collaborators, Michael attended EuSARC 2024 in June hosted in Le Pouligen, France and presented a 5-minute flash talk to an international audience of sarcoma researchers. He received excellent feedback from peers. In July, Michael also attended the Bone Research Society Annual meeting in Sheffield. Here he won the Best Poster award.

•In addition the Trustees are excited to confirm that the Charity is working together with The Bone Cancer Research Trust and jointly funding a postdoctoral 3 year research project of up to £250,000 (£125,000 funded by each charity)commencing in the 2024/25 academic year with Imperial College London led by Dr Jun Ishihara.

Project title: Overcoming osteosarcoma immunotherapy resistance by tumour-localised IL-12 driven anti-tumour immunity.

Key people: Dr Jun Ishihara, Dr Koichi Sasaki, and Dr Akinobu Hamada

Hannah's Willberry Wonder Pony Charity

Trustees' Report

BACKGROUND TO THE RESEARCH PROJECT

Despite optimal management of localised osteosarcoma disease, over 50% of patients develop metastatic disease or recurrence, which lead to poor survival outcomes in approximately 19 months. Immunotherapies, activating immune cells to attack cancers, became standard therapy in many other cancer types and enabled prolonged effects including prevention of recurrence and metastasis. However, osteosarcoma responds poorly to current standard immunotherapies due to A) inactivation of the immune system, B) resistance to immunotherapy, and C) difficulty in locally delivering drugs to tumour sites. Immunotherapies can achieve long-term effects including prevention of metastasis and recurrence. There remains huge room for improvement for immunotherapy in osteosarcoma as many patients suffer due to lack of treatment options and recurrence/metastasis.

PRELIMINARY DATA

Preliminary data from the Ishihara lab has produced promising immunotherapy protein called interleukin-12 (IL-12) that is known to successfully activate anti-tumour immune cells against several cancers. Despite its strong antitumour activity, IL-12 induces severe systemic toxicity in its native form. The lab found that several cancers including osteosarcoma increase collagen expression compared to normal tissue. They successfully reduced its toxicity, by attaching a collagen-binding domain (CBD), which enables tumour-specific delivery of IL-12.

The team hypothesise that their newly developed tumour-specific bioengineered immunotherapy (CBD-IL-12) can become a breakthrough for osteosarcoma, especially against recurrent metastatic osteosarcoma.

• We have also approved funding for a project with Southampton University total grant £130,379 over 4 years (2025-2029)

Project title: Developing a Bioengineered 3-D Multifactorial Humanized Bone Osteosarcoma Model to Assess Tumour Invasiveness and Therapeutic Response

Key people: Dr Janos Kanczler, Professor Stephen Beers, Professor Juliet Gray, Dr Yanghee Kim

BACKGROUND TO THE RESEARCH PROJECT

For the success of effective anti-bone cancer therapies, it is crucial to understand how bone cancers such as osteosarcoma switch on, progress and develop unregulated in the bone micro-environment. Various cells in combination play a critical role in the progression of the disease inside of the bone structures. Furthermore, a soft gel- like structure (cell matrix) produced by these cells is also involved in the development of the bone cancer diseases. Southampton have previously developed a lab-based model using human bone cores and a mixture of key cells to generate a 3D model of osteosarcoma growth to test a cancer drug.

In this study, the team will combine the unique bone gel matrix that they have previously developed with multiple cells in the human bone cores to further enhance this 3D model and understand if new therapies targeted to the cells in this environment or targeted to the newly developing cell matrix can prevent the onset of the osteosarcoma tumour. At the same time, the team will combine the cancer therapy agents with specialised biomaterials to help rebuild and regenerate the disease bone.

•We have also approved funding for a project with Queen Mary's University total grant £122,749 over 4 years (2025-2029)

Trustees' Report

Project title: Development of an Osteosarcoma-on-a-Chip Model to Investigate Chemoresistance and the Role of CHI3L1 in Tumour Microenvironment

Key people: Dr Stefan Verbruggen, Dr Lucia Cottone, Associate Professor Fiona Freeman, Professor Sandra Strauss

BACKGROUND TO THE PROJECT

Survival of individuals with osteosarcoma, the most common primary bone cancer which mainly affects teenagers and young adults, has not improved in the last 40 years since chemotherapy was introduced. The response to this toxic treatment is poor in nearly half of the treated patients, contributing significantly to their tumour returning, but the reasons for this failure have not been fully explained. Research into osteosarcoma has been significantly challenging due to the rarity of this disease and to the lack of good experimental systems to understand the causes of chemoresistance. Moreover, traditional drug testing using cancer cells in a dish and in small rodents have poor track records for identifying new treatments, because they are too dissimilar from the tumours.

With this project we will generate an osteosarcoma 'organ-on-a-chip', a novel experimental setup that replicates the bone environment inside a bone tumour. The organ-on-a-chip will include osteosarcoma cells donated by patients and the elements of bone found in patients. We will then use the organ-on-a-chip to investigate what makes cancer cells resistant to chemotherapy. Therefore, this project will provide a new tool to advance research and find better treatments for this paediatric cancer.

• We have also approved follow-on funding for a project with Kings College London, total grant £96,577 over 3 years (2025-2028)

Project title: Drug repurposing targeting Heme oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis

Key people: Professor Agamemnon Grigoriadis, Professor James Arnold

BACKGROUND TO THE PROJECT

Osteosarcoma is a devastating malignancy that affects children. Metastatic disease remains the most important prognostic indicator of survival, and despite advances in adjuvant chemotherapy and limb-sparing surgery, 5-year survival is 60-70%, dropping to ~20% with metastatic disease, and these frequencies have not improved.

The team at King's have made recent progress in their ongoing HWWPC-funded project that is identifying a novel target for OS metastasis therapy. The enzyme, HO-1, is made by cells in the tumour immune environment, that are normally hijacked by tumour cells to evade the immune system. The initial project uses a drug called SnMP that stops HO-1 from working, reduces OS metastasis in animal models by reactivating the immune system and enables killing of tumour cells. This project follows on from this work to show that this HO-1 pathway interacts with a target in tumour cells themselves, called FGFR. Blocking FGFR in tumour cells can inhibit metastasis but whether this affects the interaction of tumour cells with the microenvironment is not known. This project will establish for the first time whether these pathways communicate and cooperate with each other to drive OS metastasis.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

PRELIMINARY DATA

PhD student Michael Dack has used Flow cytometry to identify key cell types within the lung that could be helping osteosarcoma to spread to this site. Armed with this finding, Michael is now delving deeper into the mechanism of how these cells are helping the spread and how might the drug SnMP, be working to reactivate good immune cells to prevent osteosarcoma metastasis. This HWWPC follow-on fund gives the King's team the opportunity to continue and further the work on the current HWWPC studentship, which is in it's final year.

PROVISION OF WISHES

• In respect of Willberry's Wishes, the Charity has a small team of volunteers dedicated to helping organise and provide these equestrian-related Wishes. Interest is growing and is expected to continue to do so, as word has spread about how we can help seriously ill people and their families during the darkest of times by giving them experiences to look forward to, whilst making memories for all those involved. We share details of some of the vital Wishes we grant, but other recipients understandably wish to keep them private. We are immensely grateful for the continued support of so many people and organisations in the equestrian world, as this is critical in supporting our ability to provide Willberry's Wishes.

• Willberry's Wishes helps so many people, not only the Wishee but also their families, and we always have a number of Wishes that we are working on.

• Willberry's Wishes is about making memories, giving people things to look forward to and to forget what is happening to them even if it is just for a little while. We hope to help lots of people by granting many more Willberry's Wishes.

Financial review

The following section on Financial Review and Future Developments constitutes the Strategic Report for the purposes of the Companies Act 2006 and the Trustees confirm that they have complied with the requirements of section 4 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

•In its ninth year of operation, the Charity generated a surplus of £79,050 (previous year £83,630), all of which were unrestricted funds.
The Charity's main source of finance is donations, with a significant contribution also being made from the trading subsidiary.

Trustees' Report

Reserves policy

The Trustees of the Charity have reviewed the Charity's reserves policy in line with the existing commitments and intended future commitments to osteosarcoma research, Willberry's Wishes and estimates of future administration costs. At 31 March 2025, reserves stood at £1,698,037 (£1,618,987 in the previous year) which was substantially more than the amount required to meet these commitments. These funds are held in low risk deposit accounts with various financial institutions.

As previously highlighted, the Charity has committed to expenditure on twelve osteosarcoma research projects to date with a value of £1,155,480, of which £594,027 has been spent and the balance of £561,453 is committed expenditure over the next 4 years.

The Charity is currently in the process of preparing for the invitation of applications for further project funding requests from the research community, with the aim of awarding more fully funded research projects. It is anticipated that there will be at least 1 new project costing approximately £130,000 (project duration 4 years) committed to in each of the next 5 years, total aim to be committed £650,000.

As previously reported the Trustees are excited to confirm the continuation of collaboration with The Bone Cancer Research Trust and expect to offer funding of up to £250,000 (£125,000 funded by each charity) each year to support projects focused on improving outcomes for osteosarcoma patients. Over 5 years this would amount to future commitments of £625,000.

So in summary current reserves of £1,698,037 will fund existing commitments on grant funded research projects of £561,453, new grant funded project commitments of £650,000 over the next 5 years, new jointly funded projects with BCRT of £625,000, Wishes costs of £25,000 and 5 years operating costs of £240,000 (£48,000 per annum). These future commitments will rely on the continued generation of income from donations and interest on cash balances of £100,000 per annum. In the event that suitable research projects cannot be identified then donations to other cancer research charities could be considered.

Conclusion

The Trustees believe that the Charity has, through the kind and generous help of our supporters and volunteers, raised funds that will provide a public benefit in years to come through the funding of bone cancer research and the provision of Willberry's Wishes.

Structure, governance and management

Nature of governing document

The company is a registered charity, number 1166416, and was incorporated on 29 March 2016. It is governed by the articles and memorandum of association of that date.

The company is limited by guarantee and without a share capital. All Trustees are members of the company and guarantee to contribute to the assets of the company, in the event of it being wound up, such amounts as may be required not exceeding £10.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Our Trustees and Management

As reported in previous years, the need for employed staff has been continually under review to ensure the Charity continues to run efficiently and maximises its public benefit. The volume of work has continually increased over recent years, making it increasingly difficult to operate on a volunteer-only basis. As a result on 1st March 2025 we appointed Rachel Francis as General Manager of the charity working three days per week and as a consequence she has resigned her position of trustee. This appointment was subject to approval of the Charity Commission in line with the requirements of the charity's Articles of Association and the Charity Commission's guidance. This appointment is a real positive for the charity as Rachel has been the driving force and has very much been seen as the voice of the charity, which bears her daughter's name, for many years. Her deep knowledge of the equestrian sector where Wishes are focussed and her empathetic, considerate and sensitive engagement with recipients of Wishes (many of whom are seriously or terminally ill) and their families will be extremely important in continuing to deliver this aspect of public benefit for years to come. In addition her knowledge gained as a trustee of the scientific research environment particularly cancer / osteosarcoma and close working with other charities in the sector will assist with the ongoing development of our research activities.

At the same time as Rachel's appointment we are delighted to report that we have appointed 2 new trustees to the charity, firstly Dr Alice Goring, who is a senior molecular scientist and completed her PhD at Southampton University. Whilst studying there, she introduced us to her supervisor, Dr Claire Clarkin, who has been the Chair of our Scientific Panel for the past few years. In her capacity as Trustee, Alice will provide vital knowledge of the scientific community and will help guide us with our research activities.

Secondly, Matthew Clark who is Operations Director of Old Mill, an accountancy and financial advisory practice. Matt is also a survivor of osteosarcoma, which he was diagnosed with at 18 years of age, and he told us about his remarkable journey of recovery when we first met him. Matt then set himself the hugely onerous task of cycling over 1,000 miles to all the major equestrian eventing venues with his Travelling Willberrys, raising not only a remarkable amount of money for the Charity (over £14,000) but also increasing awareness of this hideous disease. Matt will contribute his business experience to the Charity and, crucially, a patient perspective to add to all Hannah's extraordinarily powerful testimony.

As a result of these changes the Charity is now run by 6 trustees, including Hannah's father (James Francis) and her grandmother (June Clothier). The other four Trustees are Ian Peters, former Financial Controller of Hanson plc, General Manager of Hanson Europe and Finance Director of Breedon Aggregates PLC, and Miles Toulson-Clarke, a former Main Board Director of Williams Lea Group and currently UK CEO/Group COO of Innovation Group and District Commissioner of the Wylye Valley Pony Club, plus the newly appointed trustees, Dr Alice Goring and Matthew Clark. Each of the Trustees gives their time freely, both in their roles as Trustees and carrying out day to day tasks in running the Charity.

Day to day activities of the Charity are run by the newly appointed General Manager, former trustee, Rachel Francis. Each of the Trustees have oversight of particular activities on a functional basis as follows: Alice Goring – first point of contact for research; James Francis – first point of contact for Willberry's Wishes, media and communications and research; June Clothier – trading subsidiary sales including online and at events and research; Miles Toulson-Clarke – fund raising, research and media and communications; Ian Peters – finance and legal; Matthew Clark – IT and charity operations.

The charity has adopted a conflicts of interest policy which ensures that any remuneration and employee performance decisions do not involve any connected or conflicted persons.

Trustees' Report

Recruitment and induction of new trustees

Before being appointed, a potential new trustee is encouraged to meet a number of times with the existing trustees to familiarise themselves with the work of the Charity. A newly appointed trustee receives guidance and informal training to enable them to perform their duties effectively, including governance and management, an induction to the history and current activities of the Charity, code of conduct and charity ethics. New trustees are provided with copies of key documents including the Charity's governing documents, minutes of recent Trustee's meetings and, once these are available, the latest set of financial statements and Trustees' report.

Financial Instruments

Objectives and policies

The Charity's activities expose it to a number of financial risks, principally liquidity. The Charity does not use derivative financial instruments.

Liquidity risk and interest rates

The Charity's principal financial assets are bank balances and cash, trade and other receivables, and investments.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies. The Charity has deliberately taken a conservative approach to investing its available funds during the course of the financial year which, given the current international interest environment, has generated a low rate of return. There is some residual risk to the Charity should interest rates turn negative.

In order to maintain liquidity to ensure that sufficient funds are available for ongoing operations and future developments, the Charity has adopted a conservative reserves policy.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Reference and Administrative Details

Trustees	J S Clothier
	J R Francis
	I A Peters
	C T M Toulson-Clarke
	M P Clark
	A L Goring
Charity Registration Number	1166416
Company Registration Number	10089069
	The charity is incorporated in England and Wales.
Registered Office	Manor Farm Hemington Radstock BA3 5XX
Independent Examiner	Paul Giessler FCA Francis Clark LLP Hitchcock House Hilltop Park Devizes Road Salisbury SP3 4UF

The annual report was approved by the trustees of the charity on 30/10/25 and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Statement of trustees' responsibilities

The trustees (who are also the directors of Hannah's Willberry Wonder Pony Charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 30/10/25 and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the accounts. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the accounts present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of Hannah's Willberry Wonder Pony Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')

.....

Paul Giessler FCA
Francis Clark LLP

Hitchcock House
Hilltop Park
Devizes Road
Salisbury
SP3 4UF

Date: 4 November 2025

Hannah's Willberry Wonder Pony Charity

Statement of Financial Activities for the Year Ended 31 March 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Total 2025 £
Income and Endowments from:			
Donations and legacies	3	107,674	107,674
Investment income	4	47,416	47,416
Total income		155,090	155,090
Expenditure on:			
Charitable activities	5	(76,040)	(76,040)
Total expenditure		(76,040)	(76,040)
Net income		79,050	79,050
Net movement in funds		79,050	79,050
Reconciliation of funds			
Total funds brought forward		1,618,987	1,618,987
Total funds carried forward	16	1,698,037	1,698,037

	Note	Unrestricted funds £	Total 2024 £
Income and Endowments from:			
Donations and legacies	3	123,497	123,497
Investment income	4	33,012	33,012
Total income		156,509	156,509
Expenditure on:			
Charitable activities	5	(72,879)	(72,879)
Total expenditure		(72,879)	(72,879)
Net income		83,630	83,630
Net movement in funds		83,630	83,630
Reconciliation of funds			
Total funds brought forward		1,535,357	1,535,357
Total funds carried forward	16	1,618,987	1,618,987

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2024 is shown in note 16.

Hannah's Willberry Wonder Pony Charity

(Registration number: 10089069)
Balance Sheet as at 31 March 2025

	Note	2025 £	2024 £
Fixed assets			
Investments	10	1	1
Current assets			
Debtors	11	30,390	27,638
Cash at bank and in hand	12	1,697,955	1,605,355
		1,728,345	1,632,993
Creditors: Amounts falling due within one year	13	(30,309)	(14,007)
Net current assets		1,698,036	1,618,986
Net assets		1,698,037	1,618,987
Funds of the charity:			
Unrestricted income funds			
Unrestricted funds		1,698,037	1,618,987
Total funds	16	1,698,037	1,618,987

For the financial year ending 31 March 2025 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements on pages 25 to 35 were approved by the trustees, and authorised for issue on 30/11/25 and signed on their behalf by:

.....
I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Statement of Cash Flows for the Year Ended 31 March 2025

	Note	2025 £	2024 £
Cash flows from operating activities			
Net cash income		79,050	83,630
Adjustments to cash flows from non-cash items			
Investment income	4	(47,416)	(33,012)
		31,634	50,618
Working capital adjustments			
Increase in debtors	11	(2,752)	(14,801)
Increase/(decrease) in creditors	13	16,302	(6,798)
Net cash flows from operating activities		45,184	29,019
Cash flows from investing activities			
Interest receivable and similar income	4	47,416	33,012
Net increase in cash and cash equivalents		92,600	62,031
Cash and cash equivalents at 1 April		1,605,355	1,543,324
Cash and cash equivalents at 31 March		1,697,955	1,605,355

All of the cash flows are derived from continuing operations during the above two periods.

Hannah's Willberry Wonder Pony Charity

Notes to the Financial Statements for the Year Ended 31 March 2025

1 Charity status

The charity is limited by guarantee, incorporated in England and Wales, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

The address of its registered office is:
Manor Farm
Hemington
Radstock
BA3 5XX

2 Accounting policies

Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation
Hannah's Willberry Wonder Pony Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

These financial statements are presented in Sterling, rounded to the nearest whole pound.

Going concern
The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments
All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured. Donations received through third party organisations such as Just Giving are shown net of any fees charged by these organisations.

Expenditure
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grants

Grants are recognised at the amount payable when the intention to make a grant has been communicated to the recipient and the conditions of the grant have been met.

Governance costs
These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Taxation
The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Fixed asset investments
Investments in subsidiaries are stated at historical cost less provision for any diminution in value.

Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure
Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

3 Income from donations and legacies

	Unrestricted funds General £	Total funds £
Donations and legacies;		
General donations	89,558	89,558
Donation from trading subsidiary	18,116	18,116
Total for 2025	107,674	107,674
Total for 2024	123,497	123,497

4 Investment income

	Unrestricted funds General £	Total funds £
Interest receivable and similar income;		
Interest receivable on bank deposits	47,416	47,416
Total for 2025	47,416	47,416
Total for 2024	33,012	33,012

5 Expenditure on charitable activities

	Note	Unrestricted funds General £	Total funds £
Grant funding of activities		49,801	49,801
Staff costs		2,266	2,266
Allocated support costs	6	18,872	18,872
Governance costs	6	5,101	5,101
Total for 2025		76,040	76,040
Total for 2024		72,879	72,879

In addition to the expenditure analysed above, there are also governance costs of £5,101 (2024 - £5,762) which relate directly to charitable activities. See note 6 for further details.

6 Analysis of governance and support costs

Charitable activities expenditure

	Unrestricted General £	Total 2025 £	Total 2024 £
Advertising, promotion and fundraising	7,889	7,889	2,000
Insurance	636	636	1,227
Legal and professional fees	4,196	4,196	35
Printing, postage and stationary	-	-	4
IT related costs	813	813	830
Bank fees	5,338	5,338	3,448
Governance costs	5,101	5,101	5,762
	23,973	23,973	13,306

Governance costs

	Unrestricted funds General £	Total funds £
Independent examiner fees		
Examination of the financial statements	3,061	3,061
Other fees paid to examiners	2,040	2,040
Total for 2025	5,101	5,101
Total for 2024	5,762	5,762

7 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

One trustee received reimbursed travel and subsistence of £423 (2024 £267).

No trustees have received any remuneration from the charity during the year.

Rachel Francis received one month's salary in her capacity as General Manager. Her husband James Francis, a trustee, is deemed to be a connected person.

8 Staff costs

The aggregate payroll costs were as follows:

	2025 £
Staff costs during the year were:	
Wages and salaries	2,083
Social security costs	183
	2,266

The monthly average number of persons (including senior management / leadership team) employed by the charity during the year expressed as full time equivalents was as follows:

	2025 No
	-

One employee was employed from 1 March 2025.

No employee received emoluments of more than £60,000 during the year.

9 Independent examiner's remuneration

	2025 £	2024 £
Examination of the financial statements	3,061	2,915
Other fees to examiners		
All other services	2,040	2,847

10 Fixed asset investments

	2025	2024
	£	£
Shares in group undertakings and participating interests	1	1

Details of undertakings

Details of the investments in which the charity holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking	Country of incorporation	Holding	Proportion of voting rights and shares held		Principal activity
			2025	2024	
Subsidiary undertakings					
The Willberry Wonder Pony Trading Company Limited Manor Farm, Hemington, Radstock,BA3 5XX	England and Wales	Ordinary	100%	100%	Sale of merchandise and soft toys branded with Hannah's Willberry Wonder Pony

Subsidiaries

The trading subsidiary company donates its profits to the charity. For the period 1 April 2024 to 31 March 2025, the subsidiary's turnover was £29,477 (2024 - £42,000) and total expenditure was £29,477 (2024 - £42,000).

Notes to the Financial Statements for the Year Ended 31 March 2025

11 Debtors

	2025	2024
	£	£
Due from group undertakings	30,390	27,638

12 Cash and cash equivalents

	2025	2024
	£	£
Cash at bank	1,697,955	1,605,355

13 Creditors: amounts falling due within one year

	2025	2024
	£	£
Accruals	30,309	14,007

14 Analysis of net assets between funds

	Unrestricted funds General	Total funds at 31 March 2025
	£	£
Fixed asset investments	1	1
Current assets	1,728,345	1,728,345
Current liabilities	(30,309)	(30,309)
Total net assets	1,698,037	1,698,037

	Unrestricted funds General	Total funds at 31 March 2024
	£	£
Fixed asset investments	1	1
Current assets	1,632,993	1,632,993
Current liabilities	(14,007)	(14,007)
Total net assets	1,618,987	1,618,987

15 Related party transactions

The charity has taken advantage of the exemption in Financial Reporting Standards 102 chapter 33 "Related Party Disclosure" and has not disclosed transactions with wholly owned group untertakings.

Donations made by the trustees without any conditions attached totalled £150 (2024 - £415) for the year.

Notes to the Financial Statements for the Year Ended 31 March 2025

16 Funds

	Balance at 1 April 2024 £	Incoming resources £	Resources expended £	Balance at 31 March 2025 £
Unrestricted funds				
General	1,618,987	155,090	(76,040)	1,698,037

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Balance at 31 March 2024 £
Unrestricted funds				
General	1,535,357	156,509	(72,879)	1,618,987

Hannah's Willberry Wonder Pony Charity

Detailed Statement of Financial Activities for the Year Ended 31 March 2025

	Total 2025 £	Total 2024 £
Donations and legacies		
Donation from Willberry Trading Co	18,116	24,438
Other Donations	89,558	99,059
	107,674	123,497
Investment income		
Interest Received on savings a/c	47,416	33,012
	47,416	33,012
Charitable activities		
Payroll	(2,083)	-
Employer NI	(183)	-
Insurance	(636)	(1,227)
Printing	-	(4)
Wishes costs	(4,485)	(2,250)
IT related costs	(813)	(830)
Project costs	(45,316)	(57,323)
Advertising	(7,889)	(2,000)
Compliance inc legal	(4,196)	(35)
Bank Fees	(5,338)	(3,448)
Independent examiner's remuneration	(3,061)	(2,915)
Other fees paid to independent examiners	(2,040)	(2,847)
	(76,040)	(72,879)

HANNAH'S WILLBERRY WONDER PONY CHARITY

England & Wales - Charity number 1166416

Accounts

Company registration number: 10089069
Charity registration number: 1166416

Hannah's Willberry Wonder Pony Charity

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2024

Hannah's Willberry Wonder Pony Charity

Contents

Trustees' Report	1 to 11
Reference and Administrative Details	10
Independent Examiner's Report	12 to 13
Statement of Financial Activities	14
Balance Sheet	15
Statement of Cash Flows	16
Notes to the Financial Statements	17 to 23

Hannah's Willberry Wonder Pony Charity

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2024.

Objectives and activities

Our purpose

Hannah's Willberry Wonder Pony Charity seeks to provide a public benefit by:

• promoting research into the causes, prevention and treatment of bone cancer and other types of cancer;
• promoting the health and wellbeing of people with a disability or serious illness; or, people who are affected by the disability or serious illness of a close family member; or, people who are suffering from bereavement following the death of a close family member, by providing or assisting in the provision of opportunities to ride or enjoy other equestrian related experiences; and
• assisting in the treatment and care of people suffering from bone cancer and other types of cancer and to help people caring for them.

The Charity can provide:

• grants to organisations carrying out research into bone cancer, provided that the results of the research funded will be published. In the event that the Charity is not the sole funder of any research then the grant of funding will be subject to a condition that results of research will be published and available for general use;

• grants to organisations, individuals and their families to assist those affected by bone cancer and other types of cancer;

• an experience of an equestrian nature via our Willberry's Wishes team, making precious memories to treasure forever.

Background

Hannah Francis founded the charity, Hannah's Willberry Wonder Pony, in March 2016, having been diagnosed with osteosarcoma the year before at just 17 years old. She wanted to leave a legacy and help people like her who are affected by a serious illness and wanted the Charity to raise money to fulfil two principal objectives: to fund research into osteosarcoma ("Willberry's Research); and to provide equestrian experiences to seriously ill people and their families ("Willberry's Wishes"). The Charity went from strength to strength under Hannah's leadership and has continued to grow since her passing in August 2016, raising more than £2 million to date. The Charity has funded a number of significant research projects as Hannah so dearly wished; she fought so courageously and endured such archaic treatment that she never wanted anyone else to have to go through this. Hannah lived for her horses and whilst she was ill, she ticked many equine dreams off her bucket list, and gave her the inspiration for "Willberry's Wishes". The Charity is granting Willberry's Wishes to seriously ill people in the hope that these experiences inspire others in the same way as they did Hannah, bringing a little happiness and hope during the darkest of times.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

We the Trustees are grateful to the thousands of people who have helped with donations, fundraising and spreading the word about Hannah's Willberry Wonder Pony Charity.

When necessary, the Charity engages the services of experts to assist with the running of the Charity but for the vast majority of the time it has been run by volunteers, including the Trustees, and we are very proud of everyone's efforts in keeping the cost of running the Charity to a minimum and thus ensuring maximum funds are available to apply to public benefit. However, the need for someone to manage the Charity on a day to day basis is currently under review to ensure that the Charity continues to run professionally, efficiently and maximises its public benefit. We are grateful to our volunteers for the financial protection they give us by giving many hours of their time, as well as opening their homes for meetings and providing storage space for our trading subsidiary's merchandise stock.

Our Activities During 2023/24 and Achievements to Date

We believe that the Charity has provided a public benefit in the following ways:

• In our eigth full year as a charity we have raised funds of £83,630 (previous year a deficit of £5,880) on income of £156,509 (previous year £103,613). This was another successful year in terms of funds generation, with fundraising efforts delivering good growth in income. We are incredibly grateful for the fabulous fundraising efforts and donations from so many of our supporters. We also received generous donations from individuals, trusts and other charities. The money raised will help to provide funds to meet the Charity's objectives and provide public benefit in the years to come by helping fund bone cancer research and providing Willberry's Wishes.

• The trading subsidiary, which sells Willberry branded merchandise and donates all of its profits to the Charity (£24,438 in 2023/24, previous year £12,837) has had another successful year. Demand remained steady for our Berry Ponies and for other items which were also sold at equestrian events including Badminton Horse Trials, where some riders still take to the cross-country course with their berry pony strapped to their backs, thus giving the Charity continued and valuable public profile. The portfolio of branded items offered is constantly reviewed to ensure that we keep our followers happy and achieve the best financial outcome.

• During the year, we have provided a number of Willberry's Wishes to people who are fighting, or are affected by, serious illness. Spending during the year providing these experiences amounted to £2,250 which included:

* A wonderful day at the phenomenal Badminton Horse Trials for a lovely young lady and her friend. They were wined and dined and had a full day of equestrian magic, especially as it was cross country day! We even arranged a surprise meeting with Olympic rider, Tom McEwen, who then took them into the prestigious stables on the Badminton Estate where they met some very famous horses indeed.
* A special visit from a shetland pony to meet a very poorly little girl in the hospice.
* Some carriage driving lessons were arranged for a lady who had breast cancer. This is something she had always wanted to do, and she had the most amazing experience.
*A magical day for a little girl with her siblings, a pony play day - Doris, Hannah's Shetland and a small pony for the other children travelled to meet the family. Lots of cuddles, grooming, riding and even some races! Followed with a picnic feast.
*Pony Fun Day for a brother and sister at a riding school. They got to ride a number of ponies and even had a go at mounted games! It was lovely as they were with lots of other children who were a similar age.
*A special little girl had always wanted to learn to ride so we arranged for a set of riding lessons so she could fulfil her dream.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

• We are extremely fortunate that many wonderful people in the equestrian community assist us in providing Wishes at no charge to the Charity. Since formation, many Wishes have been granted and all of these have been very well received by the recipients and we look forward to providing many more.

• In respect of medical research, we have in place an expert panel to assist the Trustees in selecting and analysing bone cancer research projects. The expert panel is headed by Dr Claire Clarkin, Associate Professor of Developmental Biology, University of Southampton, and she is very ably assisted by Dr Alice Goring, who completed a PhD related to the study of the role of blood vessels in bone diseases, and they both provide critical assistance to the Charity in managing the medical research investment process. We have continued to meet a number of clinical and academic specialists in the field of osteosarcoma research and have made significant progress in increasing the profile of the Charity in the academic and scientific communities, including advertising for PhD studentships with major universities.

• As a major milestone and to mark the incredible progress made to date, we held the first Hannah's Willberry Wonder Pony Charity Research Symposium on Thursday 5th October 2023 in London. And this was no ordinary venue, as we were so fortunate to be able to hold the event at The Goring Hotel, thanks to Hannah's close friend (and member of our Research advisory panel), Dr Alice Goring, who also did an amazing job organising the day. We welcomed researchers, supporters and friends from across the UK for a day of osteosarcoma experiences, science and discovery. Rachel Francis started the day by telling Hannah's story, from her time as a pony-mad young girl and hugely talented rider through to her initial symptoms, incorrect diagnoses and the simply dreadful day when Hannah and her family first heard the word 'osteosarcoma'. She spoke movingly about every stage of the treatment Hannah endured and the horrific side effects and lack of hope. And Rachel finished by bringing to life Hannah's passionate desire to help others and her enduring positivity and love of life. It was a perfect way to set the context for the day that followed because, above all, she highlighted the desperate need for the scientific research Hannah's charity is funding. It also reiterated so articulately why Hannah is always at the front of our minds when we are all trying so hard to fulfil her rich legacy. This was followed by an equally absorbing talk by Dr Polly Bates, Hannah's clinician at Royal United Hospital in Bath. Polly spoke in glowing terms about Hannah's fortitude and endurance, but brought starkly to life the desperately poor treatment outcomes that so many bone cancer patients face. Polly was followed by Matt Clark, who survived his diagnosis of osteosarcoma when in his late teens. Matt explained how luck played a part in his own diagnosis and treatment and he not only brought further context to why we were all assembled but he has also pledged to help Hannah's charity with a bold fundraising plan for 2024. We then had a busy day of excellent talks from all our PhD projects and it was great to hear all about their research progress. We also had some more in-depth talks from prominent research leaders, including Professor Agi Grigoriadis (King College London), Dr Helen Roberts (Middlesex University) and Professor Allie Gartland (University of Sheffield), who talked about her team's work with large scale drug screening for new treatments in osteosarcoma, which is funded by the Charity. Our first Research Symposium was a very emotional but inspiring day and a celebration of the collective hard work that is ongoing into funding and advancing osteosarcoma treatments.

Trustees' Report

• In total to date, we have identified and committed to ten research projects from leading English Universities that we are supporting with a combined value of up to £933,607, of which £57,323 was spent in the financial year. We are confident that in the coming years we will identify projects from other institutions that will assist in the identification of the causes, prevention and treatment of bone cancer and other types of cancer. These efforts will be significantly enhanced by the recent announcement that the Charity will be working together with The Bone Cancer Research Trust to offer funding of up to £250,000 (£125,000 funded by each charity) to support projects focused on improving outcomes for osteosarcoma patients.

The lead time for identifying, reviewing, approving and funding research projects remains up to 2 years. The Trustees are very conscious of the need to select prospective research projects carefully and to ensure the Charity's money is invested in a considered and appropriate way.

Our Strategy Going Forwards

• The Trustees continue to review the strategy of the Charity to ensure that it provides public benefit and has the ability to meet its objectives. The Trustees are hopeful that income generated in 2024/25 will meet our target of £100,000 and this, together with our strong reserves, will enable us to carry out the Charity's objectives in future years.
• As mentioned above, the Charity has since formation entered into, or is about to enter into, agreements to fund ten research projects.

The projects that we have funded, or are currently funding, are listed below:
oThe first is with the renowned Department of Oncology and Metabolism at Sheffield University which ran until the end of 2023, with a total cost of up to £210,000. The project can be summarised as follows:

As a result of funding from Willberry's Research, a team comprising a Post-Doctoral Researcher (Luke) and a (part funded) PhD Student (Victoria), led by Professor Allie Gartland, is testing over 5,000 existing drugs and compounds to assess their effectiveness in killing osteosarcoma cells. The team hopes to identify potentially useful new drugs and pathways to develop more effective treatments to improve patient responses. Because the drugs being screened have already been approved for human use, the identification of new drug candidates could potentially be more timely and reach the clinic in a much shorter time as a result.

The main current therapeutic approach for osteosarcoma is a combination of methotrexate, docorubicin, cisplatin, and/or ifosfamide associated with surgery. Unfortunately, not all patients respond to these chemotherapy drugs, as their tumour becomes 'chemo-resistant' and their overall 5-year survival rate is drastically reduced. The need for alternative, more effective treatments to increase the survival rates of osteosarcoma patients is clear. The scientific team being funded by Willberry's Research is using 'High throughput screening' (or HTS) of compound 'libraries' to identify whether existing drugs can be used in osteosarcoma.

Excitingly, out of the 4,400 drugs which have been screened so far, 550 have been found to have a negative effect on the growth of osteosarcoma cells (growing in a dish) at high doses.

Trustees' Report

o The Charity has also part-funded a PhD student at, Sheffield University, Manchester University and two at the University of Southampton, with a combined funding of £183,000 over 3 years. All four projects were focussed on Osteosarcoma.

o Hannah Smith was our first PhD student and based at Southampton University supervised by Prof Stephen Beers Dr Juliet Gray snf Dr Janos Kanzcelr. Osteosarcoma is the most common bone sarcoma in adolescents and has a poor outlook. Novel treatments for this poorly met patient group are clearly needed but their development is hampered by the complexity of the disease and the environment in which it grows. Hannah was developing 3D models of osteosarcoma to gain a better understanding of the interactions between the osteosarcoma tumour and its surrounding environment. Osteosarcoma is an incredibly complex type of cancer and currently very little is known about the environment in which it grows. This project focused initially on the drug mifamurtide (also known as Mepact) which is used in patients, but to which not all respond, to understand how this drug works and potentially how to make it work better in more patients. Her PhD is to develop a 3D model of osteosarcoma, which will enable the testing of new drugs and therapies. This is done by using bone from patients who have had hip replacement surgery and inserting osteosarcoma cells into these bone cores. These cores are then positioned to enable blood vessels to interact with the bone, so that osteosarcoma cells remain alive, and the effect of different therapies can be tested.

o Another project at Southampton University, with Belle Creith as a PhD student, started in October 2019 and was supervised by Dr Claire Clarkin, Professor Richard Oreffo and Professor Sumeet Mahajan. This was focused on the early detection of osteosarcoma, which is so important, as we are only too aware how quickly this cancer can spread. The project has been using some very advanced imaging techniques to look at the fibres which are present within osteosarcoma and healthy bone biopsies. Belle is looking at whether differences in these bone fibres in diseased versus healthy bone might be early indicators for osteosarcoma and a measure of metastasis. There have been some really good images and findings so far and results of this project should be published soon.

o And our PhD project with Manchester University, which also started in October 2019, builds on the success of an earlier two-year research grant funded by the charity, Friends of Rosie Children's Cancer Research Fund. In common with the initial project, our project is being led by Dr Katherine Finegan, MRPharmS, with Alex, our PhD student. Previous work performed in this lab has found that a protein called ERK5 can promote the progression of osteosarcoma. It has also been found that high levels of the ERK5 protein can increase the chances of chemotherapy resistance and the spread of osteosarcoma around the body. Therefore, higher levels of ERK5 are linked to a reduced chance of survival in patients. Initial evidence has found that, by removing ERK5, tumour cells and immune cells are no longer able to communicate with each other. This is really positive data from this lab group as it is the communication between the tumour cells and the immune cells which allows the cancer to spread around the body. It is currently unknown how this happens, but removing ERK5 has shown to stop the spread of cancer to the lungs in models of the disease which have been used in the lab. It is really important to fully understand how this happens in order to effectively treat osteosarcoma and to develop this treatment for patient use in the future. This project aims to find out exactly how ERK5 works in the progression of osteosarcoma and determine whether removing ERK5 can improve the response to chemotherapy. This is a promising new avenue for the treatment of osteosarcoma.

o Another of our projects is a first fully-funded PhD studentship, based at Middlesex University within the Centre for Investigative & Diagnostic Oncology. The research, led by Dr Helen Roberts (Senior Lecturer), aims to unravel the complex cellular and environmental control of how osteosarcoma, the rare type of bone cancer the Charity is focused on, spreads to other tissues such as the lungs.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

For the past 30 years, survival rates in osteosarcoma patients have remained unchanged, partly due to the lack of research into why the tumour spreads and what initiates this process. Preclinical and clinical evidence highlights that osteosarcoma tumours likely reside in the bone environment due to 'protective' interactions with bone cells. It is hypothesised that disruption of these protective interactions causes the tumour to move from the bone to the lungs in a process called metastasis. The project is investigating why osteosarcoma tumours metastasise to the lungs and is using cutting edge cell-based assays to define not only the role of the bone cells, but also the lung environment. The project draws on the tissue engineering experience of Dr Scott Roberts (Senior Lecturer in Translational Skeletal Research, RVC), who has spent over a decade developing laboratory grown tissues that can be used for regenerative medicine and the investigation of disease processes. Here is an update from our researcher:

• "Our project aims to identify how osteosarcoma cells spread to other tissues such as the lungs. We have identified spheroid-like structures formed from osteosarcoma cells which we have termed 'Migratory Bodies'. These Migratory Bodies divide, reattach, and express increased gene expression of stem cell markers, suggesting that they contain tumour initiating (cancer stem) cells and are therefore an ideal model for studying how osteosarcoma cells spread to other tissues.
• "We have also looked at the effect of secreted factors from two types of bone cells on osteosarcoma cell migration. The data show that when osteosarcoma cells are cultured with factors secreted by osteoclasts (cells that break down bone) and mesenchymal stromal cells (MSCs; cells with the unique ability to develop into specialised cell types), Migratory Body formation is suppressed. Thus, we believe that both MSCs and osteoclasts secrete factors that modulate Migratory Body formation and thus osteosarcoma cell migration. By investigating these findings further, we hope to understand some of the mechanisms that allow osteosarcoma to spread to other tissues."

o In addition, we are currently funding a PhD project with Kings College London . This is a three-year research project which is taking place under the expert guidance of Professor Agamemnon Grigoriadis. The project is focusing on understanding and preventing the growth of cancer cells in osteosarcoma patients, as well as looking to stop the spread of cancer around the body. The ability of osteosarcoma to metastasise is what makes it so aggressive and therefore focusing the research on this is really important. This project is looking at repurposing a pre-existing drug, which is currently used to treat neonatal jaundice, to block the action of HO-1. HO-1 is a factor which is produced by osteosarcoma patients and prevents the activation of the immune system. By 'kick-starting' the immune system into action, the project will assess if the chemotherapy drugs are able to fight the cancer and stop it from moving to other areas of the body.

o The Charity has recently invited follow-on projects from the initial tranche of research identified above and we are pleased to confirm 2 four-year PhD student grants have been awarded for a total value of £245,000. The projects are:

o Middlesex University (Dr Helen Roberts) - the research project entitled Suppress Osteosarcoma: Targeting Osteoclast-Tumour Interactions to suppress Osteosarcoma metastasis. There is a hypothesis that Osteosarcoma establishes itself in bones by interacting with osteoclasts, specialised cells responsible for breaking down bone tissue. Disrupting this interaction allows OS to spread to the lungs. In our prior study, we identified 'Migratory Bodies' (MBs) as a valuable laboratory model for studying OS spread. Osteoclast factors slow down MBs, but the drug zoledronic acid (used to treat osteoporosis) can counteract this effect. In the proposed study we will use genetic engineering, to unravel how OS spreads, with a particular focus on potential treatment targets STAT3 and MMP9. Additionally, we plan to examine OS metabolism and employ a unique model to enhance our understanding of metastasis. This research holds promise for refining OS treatment strategies, incorporating insights into osteoclast interactions, with the ultimate goal of improving outcomes for patients.

o Kings College London (Professor Agamemnon Grigoriadis) - a Novel FGFR-HO-1 Axis for Targeting Osteosarcoma Pathogenesis and Metastasis. Osteosarcoma is a devastating malignancy that affects children. Metastatic disease remains the most important prognostic indicator of survival, and despite advances in adjuvant chemotherapy and limb-sparing surgery, 5-year survival is 60-70%, dropping to ~20% with metastatic disease, and these frequencies have not improved. We have made recent progress from an ongoing HWWPC-funded project that is identifying a novel target for OS metastasis therapy. The enzyme, HO-1, is made by cells in the tumour immune environment that are normally hijacked by tumour cells to evade the immune system. Using a drug called SnMP that stops HO-1 from working, this reduces OS metastasis in models by reactivating the immune system, enabling killing of tumour cells. The current HWWPC proposal aims to follow on from this work, to show that this HO-1 pathway interacts with a target in tumour cells themselves, called FGFR. We have shown that blocking FGFR in tumour cells can inhibit metastasis but whether this affects the interaction of tumour cells with the microenvironment is not known. This project will establish for the first time whether these pathways communicate and cooperate with each other to drive OS metastasis. This will open the door to novel combinatorial therapies using multiple drug combinations that will reduce metastatic burden and increase patient survival.

o In addition the trustees are excited to confirm that the Charity will be working together with The Bone Cancer Research Trust to joint fund a postdoctoral 3 year research project of up to £250,000 (£125,000 funded by each charity) in the 2024/25 academic year with Imperial College London led by Dr Jun Ishihara to support projects focused on improving outcomes for osteosarcoma patients. Treatment for osteosarcoma has not changed for several decades and still relies on a cocktail of toxic chemotherapies. New, targeted treatments, with less immediate and long-term effects are desperately needed to ensure more patients survive and thrive after treatment. Immunotherapy is emerging as an effective treatment in many cancers and works by helping the immune system find and attack cancer cells. With treatment options for osteosarcoma patients remaining unchanged for decades it's vital that we investigate options such as immunotherapy for our patients and try to translate the progress being made in other cancers to osteosarcoma. We're delighted to be able to do this in collaboration with the Bone Cancer Research Trust who wholeheartedly have the same aim as us, to offer osteosarcoma patients kinder and more effective treatment options."
o A protein named interleukin-12 (IL-12) is known to successfully activate anti-tumour immune cells against several cancers. However, despite showing strong antitumour activity, IL-12 also induces severe toxicity to other tissues. Dr Ishihara has successfully been able to reduce IL-12's toxicity by incorporating an additional fragment (tumour-targeted domain - TTD) to the IL-12 protein that enables its delivery selectively to the tumour. TTD-IL-12 accumulates in the tumour due to the targeted protein being present in the tumour's blood vessels. TTD-IL-12 is effective in laboratory models for other cancer types and in initial osteosarcoma laboratory models. This project aims to extend the results found in other cancers to a full range of laboratory models of osteosarcoma. The research also aims to determine if a combination of TTD-IL-12 with doxorubicin (part of the current MAP chemotherapy regime) can offer additional benefit.

• In respect of Willberry's Wishes, the Charity has a small team of volunteers dedicated to helping organise and provide these equestrian-related Wishes. Interest is growing and is expected to continue to do so, as word has spread about how we can help seriously ill people and their families during the darkest of times by giving them experiences to look forward to, whilst making memories for all those involved. We share details of some of the vital Wishes we grant, but other recipients understandably wish to keep them private. We are immensely grateful for the continued support of so many people and organisations in the equestrian world, as this is critical in supporting our ability to provide Willberry's Wishes.

• Willberry's Wishes helps so many people, not only the Wishee but also their families, and we always have a number of Wishes that we are working on.

Trustees' Report

•Willberry's Wishes is about making memories, giving people things to look forward to and to forget what is happening to them even if it is just for a little while. We hope to help lots of people by granting many more Willberry's Wishes.

Financial review

The following section on Financial Review and Future Developments constitutes the Strategic Report for the purposes of the Companies Act 2006 and the trustees confirm that they have complied with the requirements of section 4 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

• In its eighth year of operation, the Charity generated a surplus of £83,630 (previous year a deficit of £5,880), all of which were unrestricted funds.

The Charity's main source of finance is donations, with a significant contribution also being made from the trading subsidiary.

Reserves policy

The Trustees of the Charity have reviewed the Charity's reserves policy in line with the existing commitments and intended future commitments to osteosarcoma research, Willberry's Wishes and estimates of future administration costs. At 31 March 2024, reserves stood at £1,618,987 (£1,535,357 in the previous year) which was substantially more than the amount required to meet these commitments. These funds are held in low risk deposit accounts with various financial institutions.

As previously highlighted, the Charity has committed to date to expenditure on ten osteosarcoma research projects with a value of £933,607, of which £516,137 has been spent and the balance of £417,470 is committed expenditure over the next 4 years.

The Charity is currently in the process of preparing for the invitation of applications for further project funding requests from the research community, with the aim of awarding more fully funded research projects. It is anticipated that there will be at least 2 new projects costing a combined £250,000 (over 4 years) committed to in each of the next 3 years.

In addition, as stated above, the Trustees are excited to confirm that the Charity will be working together with The Bone Cancer Research Trust to offer funding of up to £250,000 (£125,000 funded by each charity) in the 2024/25 academic year to support projects focused on improving outcomes for osteosarcoma patients.It is anticipated that this working relationship will directly lead to further research opportunities in future years with the aim of committing to further large (circa £250,000) projects, jointly funded circa £125,000 by each charity.

In addition the Charity will continue to fund Willberry's Wishes.

Conclusion

The Trustees believe that the Charity has, through the kind and generous help of our supporters and volunteers, raised funds that will provide a public benefit in years to come through the funding of bone cancer research and the provision of Willberry's Wishes.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Structure, governance and management

Nature of governing document

The company is a registered charity, number 1166416, and was incorporated on 29 March 2016. It is governed by the articles and memorandum of association of that date.

The company is limited by guarantee and without a share capital. All Trustees are members of the company and guarantee to contribute to the assets of the company, in the event of it being wound up, such amounts as may be required not exceeding £10.

Our Trustees

The Charity is currently run by 5 trustees, including Hannah's parents (Rachel and James Francis) and her grandmother (June Clothier). The other two Trustees are Ian Peters, former Financial Controller of Hanson plc, General Manager of Hanson Europe and Finance Director of Breedon Aggregates PLC, and Miles Toulson-Clarke, a former Main Board Director of Williams Lea Group and currently UK CEO/Group COO of Innovation Group and District Commissioner of the Wylye Valley Pony Club. Each of the Trustees gives their time freely, both in their roles as Trustees and carrying out day to day tasks in running the Charity.

Day to day activities of the Charity are delegated to each of the Trustees on a functional basis as follows: Rachel Francis – first point of contact, Willberry's Wishes and fundraising and research; James Francis – Willberry's Wishes, media and communications and research; June Clothier – trading subsidiary sales including online and at events and research; Miles Toulson-Clarke – research and media and communications; Ian Peters – finance and legal.

Induction and training of trustees

Before being appointed, a potential new trustee is encouraged to attend a number of trustee meetings to familiarise themselves with the work of the Charity. A newly appointed trustee receives guidance and informal training to enable them to perform their duties effectively, including governance and management, an induction to the history and current activities of the Charity, code of conduct and charity ethics. New trustees are provided with copies of key documents including the Charity's governing documents, minutes of recent trustees meetings and, once these are available, the latest set of financial statements and trustees' report.

Financial Instruments

Objectives and policies

The Charity's activities expose it to a number of financial risks, principally liquidity. The Charity does not use derivative financial instruments.

Trustees' Report

Liquidity risk and interest rates

The Charity's principal financial assets are bank balances and cash, trade and other receivables, and investments.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies. The Charity has deliberately taken a conservative approach to investing its available funds during the course of the financial year which, given the current international interest environment, has generated a low rate of return. There is some residual risk to the Charity should interest rates turn negative.

In order to maintain liquidity to ensure that sufficient funds are available for ongoing operations and future developments, the Charity has adopted a conservative reserves policy.

Reference and Administrative Details

Trustees	J S Clothier J R Francis R Francis I A Peters C T M Toulson-Clarke
Charity Registration Number	1166416
Company Registration Number	10089069
	The charity is incorporated in England and Wales.
Registered Office	Manor Farm Hemington Radstock BA3 5XX
Independent Examiner	Paul Giessler FCA Francis Clark LLP Hitchcock House Hilltop Park Devizes Road Salisbury SP3 4UF

The annual report was approved by the trustees of the charity on 21/10/24 and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Statement of trustees' responsibilities

The trustees (who are also the directors of Hannah's Willberry Wonder Pony Charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 21/10/24 and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the accounts. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the accounts present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of Hannah's Willberry Wonder Pony Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')

.....
Paul Giessler FCA
Francis Clark LLP

Hitchcock House
Hilltop Park
Devizes Road
Salisbury
SP3 4UF

Date: 7 November 2024

Hannah's Willberry Wonder Pony Charity

Statement of Financial Activities for the Year Ended 31 March 2024 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Total 2024 £
Income and Endowments from:			
Donations and legacies	3	123,497	123,497
Investment income	4	33,012	33,012
Total income		156,509	156,509
Expenditure on:			
Charitable activities	5	(72,879)	(72,879)
Total expenditure		(72,879)	(72,879)
Net income		83,630	83,630
Net movement in funds		83,630	83,630
Reconciliation of funds			
Total funds brought forward		1,535,357	1,535,357
Total funds carried forward	15	1,618,987	1,618,987

	Note	Unrestricted funds £	Total 2023 £
Income and Endowments from:			
Donations and legacies	3	91,346	91,346
Investment income	4	12,267	12,267
Total income		103,613	103,613
Expenditure on:			
Charitable activities	5	(109,493)	(109,493)
Total expenditure		(109,493)	(109,493)
Net expenditure		(5,880)	(5,880)
Net movement in funds		(5,880)	(5,880)
Reconciliation of funds			
Total funds brought forward		1,541,237	1,541,237
Total funds carried forward	15	1,535,357	1,535,357

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2023 is shown in note 15.

Hannah's Willberry Wonder Pony Charity

Statement of Financial Activities for the Year Ended 31 March 2024 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Total 2024 £
Income and Endowments from:			
Donations and legacies	3	123,497	123,497
Investment income	4	33,012	33,012
Total income		156,509	156,509
Expenditure on:			
Charitable activities	5	(72,879)	(72,879)
Total expenditure		(72,879)	(72,879)
Net income		83,630	83,630
Net movement in funds		83,630	83,630
Reconciliation of funds			
Total funds brought forward		1,535,357	1,535,357
Total funds carried forward	15	1,618,987	1,618,987

	Note	Unrestricted funds £	Total 2023 £
Income and Endowments from:			
Donations and legacies	3	91,346	91,346
Investment income	4	12,267	12,267
Total income		103,613	103,613
Expenditure on:			
Charitable activities	5	(109,493)	(109,493)
Total expenditure		(109,493)	(109,493)
Net expenditure		(5,880)	(5,880)
Net movement in funds		(5,880)	(5,880)
Reconciliation of funds			
Total funds brought forward		1,541,237	1,541,237
Total funds carried forward	15	1,535,357	1,535,357

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2023 is shown in note 15.

Hannah's Willberry Wonder Pony Charity

(Registration number: 10089069)
Balance Sheet as at 31 March 2024

	Note	2024 £	2023 £
Fixed assets			
Investments	9	1	1
Current assets			
Debtors	10	27,638	12,837
Cash at bank and in hand	11	1,605,355	1,543,324
		1,632,993	1,556,161
Creditors: Amounts falling due within one year	12	(14,007)	(20,805)
Net current assets		1,618,986	1,535,356
Net assets		1,618,987	1,535,357
Funds of the charity:			
Unrestricted income funds			
Unrestricted funds		1,618,987	1,535,357
Total funds	15	1,618,987	1,535,357

For the financial year ending 31 March 2024 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements on pages 14 to 23 were approved by the trustees, and authorised for issue on 21/10/24 and signed on their behalf by:

.....
I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Statement of Cash Flows for the Year Ended 31 March 2024

	Note	2024 £	2023 £
Cash flows from operating activities			
Net cash income/(expenditure)		83,630	(5,880)
Adjustments to cash flows from non-cash items			
Investment income	4	(33,012)	(12,267)
		50,618	(18,147)
Working capital adjustments			
(Increase)/decrease in debtors	10	(14,801)	7,284
(Decrease)/increase in creditors	12	(6,798)	17,805
Net cash flows from operating activities		29,019	6,942
Cash flows from investing activities			
Interest receivable and similar income	4	33,012	12,267
Net increase in cash and cash equivalents		62,031	19,209
Cash and cash equivalents at 1 April		1,543,324	1,524,115
Cash and cash equivalents at 31 March		1,605,355	1,543,324

All of the cash flows are derived from continuing operations during the above two periods.

Hannah's Willberry Wonder Pony Charity

Notes to the Financial Statements for the Year Ended 31 March 2024

1 Charity status

The charity is limited by guarantee, incorporated in England and Wales, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

The address of its registered office is:
Manor Farm
Hemington
Radstock
BA3 5XX

2 Accounting policies

Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation
Hannah's Willberry Wonder Pony Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern
The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments
All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured. Donations received through third party organisations such as Just Giving are shown net of any fees charged by these organisations.

Expenditure
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grants

Grants are recognised at the amount payable when the intention to make a grant has been communicated to the recipient and the conditions of the grant have been met.

Governance costs
These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Taxation
The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Fixed asset investments
Investments in subsidiaries are stated at historical cost less provision for any diminution in value.

Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure
Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

3 Income from donations and legacies

	Unrestricted funds General £	Total funds £
Donations and legacies;		
General donations	99,059	99,059
Donation from trading subsidiary	24,438	24,438
Total for 2024	123,497	123,497
Total for 2023	91,346	91,346

4 Investment income

	Unrestricted funds General £	Total funds £
Interest receivable and similar income;		
Interest receivable on bank deposits	33,012	33,012
Total for 2024	33,012	33,012
Total for 2023	12,267	12,267

5 Expenditure on charitable activities

	Note	Unrestricted funds General £	Total funds £
Grant funding of activities		59,573	59,573
Allocated support costs	6	7,544	7,544
Governance costs	6	5,762	5,762
Total for 2024		72,879	72,879
Total for 2023		109,493	109,493

In addition to the expenditure analysed above, there are also governance costs of £5,762 (2023 - £4,213) which relate directly to charitable activities. See note 6 for further details.

6 Analysis of governance and support costs

Charitable activities expenditure

	Unrestricted General £	Total 2024 £	Total 2023 £
Office expenses	2,000	2,000	1,618
Insurance	1,227	1,227	545
Legal and professional fees	35	35	-
Printing, postage and stationary	4	4	44
Bank fees	3,448	3,448	2,073
Governance costs	5,762	5,762	4,213
IT related costs	830	830	-
	13,306	13,306	8,493

Governance costs

	Unrestricted funds General £	Total funds £
Independent examiner fees		
Examination of the financial statements	2,915	2,915
Other fees paid to examiners	2,847	2,847
Total for 2024	5,762	5,762
Total for 2023	4,213	4,213

7 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Two trustees received reimbursed travel and subsistence of £267 (2023 £1,381) during the year.

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

8 Independent examiner's remuneration

	2024 £	2023 £
Examination of the financial statements	2,915	2,650
Other fees to examiners		
All other services	2,847	1,563

9 Fixed asset investments

	2024 £	2023 £
Shares in group undertakings and participating interests	1	1

Details of undertakings

Details of the investments in which the charity holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking	Country of incorporation	Holding	Proportion of voting rights and shares held 2024	Proportion of voting rights and shares held 2023	Principal activity
Subsidiary undertakings					
The Willberry Wonder Pony Trading Company Limited Manor Farm, Hemington, Radstock,BA3 5XX	England and Wales	Ordinary	100%	100%	Sale of merchandise and soft toys branded with Hannah's Willberry Wonder Pony

Subsidiaries

The trading subsidiary company donates its profits to the charity. For the period 1 April 2023 to 31 March 2024, the subsidiary's turnover was £42,000 (2023 - £38,602) and total expenditure was £42,000 (2023 - £38,602).

10 Debtors

	2024	2023
	£	£
Due from group undertakings	27,638	12,837

11 Cash and cash equivalents

	2024	2023
	£	£
Cash at bank	1,605,355	1,543,324

12 Creditors: amounts falling due within one year

	2024	2023
	£	£
Accruals	14,007	20,805

13 Analysis of net assets between funds

	Unrestricted funds General	Total funds at 31 March 2024
	£	£
Fixed asset investments	1	1
Current assets	1,632,993	1,632,993
Current liabilities	(14,007)	(14,007)
Total net assets	1,618,987	1,618,987

	Unrestricted funds General	Total funds at 31 March 2023
	£	£
Fixed asset investments	1	1
Current assets	1,556,161	1,556,161
Current liabilities	(20,805)	(20,805)
Total net assets	1,535,357	1,535,357

14 Related party transactions

The charity has taken advantage of the exemption in Financial Reporting Standards 102 chapter 33 "Related Party Disclosure" and has not disclosed transactions with wholly owned group untertakings.

Donations made by the trustees without any conditions attached totalled £415 (2023 - £150) for the year.

Notes to the Financial Statements for the Year Ended 31 March 2024

15 Funds

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Balance at 31 March 2024 £
Unrestricted funds				
General	1,535,357	156,509	(72,879)	1,618,987

	Balance at 1 April 2022 £	Incoming resources £	Resources expended £	Balance at 31 March 2023 £
Unrestricted funds				
General	1,541,237	103,613	(109,493)	1,535,357

HANNAH'S WILLBERRY WONDER PONY CHARITY

England & Wales - Charity number 1166416

Accounts

Company registration number: 10089069

Charity registration number: 1166416

Hannah's Willberry Wonder Pony Charity

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2023

Hannah's Willberry Wonder Pony Charity

Contents

Trustees' Report	1 to 10
Reference and Administrative Details	9
Independent Examiner's Report	11 to 12
Statement of Financial Activities	13
Balance Sheet	14
Statement of Cash Flows	15
Notes to the Financial Statements	16 to 23

Hannah's Willberry Wonder Pony Charity

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2023.

Objectives and activities

Our purpose

Hannah's Willberry Wonder Pony Charity seeks to provide a public benefit by:

• promoting research into the causes, prevention and treatment of bone cancer and other types of cancer;
• promoting the health and wellbeing of people with a disability or serious illness; or, people who are affected by the disability or serious illness of a close family member; or, people who are suffering from bereavement following the death of a close family member, by providing or assisting in the provision of opportunities to ride or enjoy other equestrian related experiences; and
• assisting in the treatment and care of people suffering from bone cancer and other types of cancer and to help people caring for them.

The Charity can provide:

• grants to organisations carrying out research into bone cancer, provided that the results of the research funded will be published. In the event that the Charity is not the sole funder of any research then the grant of funding will be subject to a condition that results of research will be published and available for general use;
• grants to organisations, individuals and their families to assist those affected by bone cancer and other types of cancer;
• an experience of an equestrian nature via our Willberry's Wishes team, making precious memories to treasure forever.

Background

Hannah Francis founded the charity, Hannah's Willberry Wonder Pony in March 2016, having been diagnosed with osteosarcoma the year before at just 17 years old. She wanted to leave a legacy and help people like her who are affected by a serious illness and wanted the Charity to raise money to fulfil two principal objectives; to fund research into osteosarcoma and to provide equestrian experiences to seriously ill people. The Charity went from strength to strength under Hannah's leadership and has continued to grow since her passing in August 2016, raising more than £2 million to date. The Charity has funded a number of significant research projects as Hannah so dearly wished; she fought so courageously and endured such archaic treatment that she never wanted anyone else to have to go through this. Hannah lived for her horses and whilst she was ill, she ticked many equine dreams off her bucket list, and gave her the inspiration for "Willberry's Wishes". The Charity is granting Willberry's Wishes to seriously ill people in the hope that these experiences inspire others in the same way as they did Hannah, bringing a little happiness and hope during the darkest of times. We the Trustees are grateful to the thousands of people who have helped with donations, fundraising and spreading the word about Hannah's Willberry Wonder Pony Charity.

When necessary, the Charity engages the services of experts to assist with the running of the Charity but for the vast majority of the time it has been run by volunteers, including the Trustees, and we are very proud of everyone's efforts in keeping the cost of running the Charity to a minimum and thus ensuring maximum funds are available to apply to public benefit, however the need for full time staff is continually under review to ensure the Charity continues to run efficiently. With the current cost of living crisis impacting many businesses and charities, we are especially grateful to our volunteers for the financial protection they give us by giving many hours of their time, as well as opening their homes for meetings and providing storage space for our trading subsidiary's merchandise stock.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Our activities during 2022/23 and achievements to date

We believe that the Charity has provided a public benefit in the following ways:

• In our seventh full year as a charity as anticipated funds generated were lower than the previous year, £103,613 (previous year £140,777) and consequently a deficit of £5,880 was recorded (previous year £6,468 surplus). The fundraising environment has been more challenging in part due to the impact of the increased cost of living but we are incredibly grateful for the fabulous fundraising efforts and generous donations from so many of our supporters. We also received generous donations from individuals, trusts and other charities. The money raised will help to provide funds to meet the Charity's long-term objectives and provide public benefit in the years to come by helping fund bone cancer research and providing Willberry's Wishes.

• The trading subsidiary, which sells Willberry branded merchandise and donates all of its profits (£12,837 in 2022/23, previous year £10,121) to the Charity, has had another successful year. Demand remained steady for our Berry Ponies and for other items which were also sold at equestrian events including at the Pratoni eventing competition in Italy and online. The portfolio of branded items offered is constantly reviewed to ensure that we keep our followers happy and achieve the best financial outcome.

• During the year, we have provided a number of Willberry's Wishes to people who are fighting, or are affected by, serious illness. Spending during the year providing these experiences amounted to £8,106 which included:

o A magical day for a little girl and her brother on a farm with Hannah's pony, Doris, and her friend, Teddy the Shetland
o A trip to Blair Castle to walk the course and meet international event riders, Pippa Funnell, and Matt Heath
o A yard visit to meet the one and only Valegro
o A horse camp with her own horse for Charlotte at Aston Le Walls summer camp
o A ride on the gallops at Newmarket and a tour of the training grounds and jockey rooms, with sincere thanks to the Jockey Club
o A training session and fantastic experiences at Jonty Evans' yard
o Two amazing visits to the London International Horse Show, including meeting Father Christmas and a ride on his sleigh
o We were also very pleased to work with another charity, Sullivan's Heroes, to help provide funding for adaptations to a child's home to meet medical needs and improve comfort

We are extremely fortunate that many wonderful people in the equestrian community assist us in providing Wishes at no charge to the Charity. Since formation, many Wishes have been granted and all of these have been very well received by the recipients and we look forward to providing many more.

In respect of medical research, we have in place an expert panel to assist the Trustees in selecting and analysing bone cancer research projects. The expert panel is headed by Dr Claire Clarkin, Associate Professor of Developmental Biology, University of Southampton, and she is very ably assisted by Dr Alice Goring, who completed a PhD related to the study of the role of blood vessels in bone diseases, and they both provide critical assistance to the Charity in managing the medical research investment process. We have continued to meet numerous clinical and academic specialists in the field of osteosarcoma research and have made significant progress in increasing the profile of the Charity in the academic and scientific communities, including advertising for PhD studentships with major universities. We will be holding an osteosarcoma symposium in London in October 2023 where we will be sharing feedback on the research projects currently being funded and our plans for the future.

Trustees' Report

To date, we have identified and committed to seven projects from leading English Universities that we are supporting with a combined value of up to £579,608, of which £92,894 was spent in the financial year. We are confident that in the coming years we will identify projects from other institutions that will assist in the identification of the causes, prevention and treatment of bone cancer and other types of cancer. These efforts will by significantly enhanced by the recent announcement that the Charity will be working together with The Bone Cancer Research Trust to offer funding of up to £250,000 (£125,000 funded by each charity) to support projects focused on improving outcomes for osteosarcoma patients.

The lead time for identifying, reviewing, approving, and funding research projects remains up to 2 years. The Trustees are very conscious of the need to select prospective research projects carefully and to ensure the Charity's money is invested in a considered and appropriate way.

Our Strategy Going Forwards

The Trustees continue to review the strategy of the Charity to ensure that it provides public benefit and has the ability to meet its objectives. The Trustees are hopeful that income generated in 2023/24 will meet our target of £100,000 and this, together with our strong reserves position, will enable us to carry out the Charity's objectives in future years.

As mentioned above, the Charity has entered into agreements to fund seven research projects. Due to the impact of Covid-19, several of these projects were partially delayed as access to university laboratory facilities were severely restricted, firstly due to the lockdown itself and then the necessary reduction in capacity to provide a safe environment in which to work and observe social distancing recommendations which occurred post the lockdown. The cost impact of these delays has been minimal.

It is shocking to note that chemotherapy treatment for osteosarcoma hasn't changed in the past 30 years and has a limited success rate. The treatment is barbaric and causes suffering and horrific side effects. New ways to fight this devastating disease are urgently needed.

The projects that we are currently funding are listed below:

o The first is with the renowned Department of Oncology and Metabolism at Sheffield University which runs until the end of 2023, with a total cost of up to £227,000. The project can be summarised as follows:

As a result of funding from Willberry's Research, a team comprising a Post-Doctoral Researcher (Luke) and a PhD Student (Victoria), led by Professor Allie Gartland, is testing over 5,000 existing drugs and compounds to assess their effectiveness in killing osteosarcoma cells. The team hopes to identify potentially useful new drugs and pathways to develop more effective treatments to improve patient responses. Because the drugs being screened have already been approved for human use, the identification of new drug candidates could potentially be timelier and reach the clinic in a much shorter time as a result.

The main current therapeutic approach for osteosarcoma is a combination of methotrexate, docorubicin, cisplatin, and/or ifosfamide associated with surgery. Unfortunately, not all patients respond to these chemotherapy drugs, as their tumour becomes 'chemo-resistant' and their overall 5-year survival rate is drastically reduced. The need for alternative, more effective treatments to increase the survival rates of osteosarcoma patients is clear. The scientific team being funded by Willberry's Research is using 'High throughput screening' (or HTS) of compound 'libraries' to identify whether existing drugs can be used in osteosarcoma.

Trustees' Report

Excitingly, out of the 4,400 drugs which have been screened so far, 550 have been found to have a negative effect on the growth of osteosarcoma cells (growing in a dish) at high doses.

o Another of our projects is a first fully funded PhD studentship, based at Middlesex University within the Centre for Investigative & Diagnostic Oncology. The research, led by Dr Helen Roberts (Senior Lecturer), aims to unravel the complex cellular and environmental control of how osteosarcoma, the rare type of bone cancer the Charity is focused on, spreads to other tissues such as the lungs.

For the past 30 years, survival rates in osteosarcoma patients have remained unchanged, partly due to the lack of research into why the tumour spreads and what initiates this process. Preclinical and clinical evidence highlights that osteosarcoma tumours likely reside in the bone environment due to 'protective' interactions with bone cells. It is hypothesised that disruption of these protective interactions causes the tumour to move from the bone to the lungs in a process called metastasis. The project is investigating why osteosarcoma tumours metastasise to the lungs and is using cutting edge cell-based assays to define not only the role of the bone cells, but also the lung environment. The project draws on the tissue engineering experience of Dr Scott Roberts (Senior Lecturer in Translational Skeletal Research, RVC), who has spent over a decade developing laboratory grown tissues that can be used for regenerative medicine and the investigation of disease processes. Here is an update from our researcher:

"Our project aims to identify how osteosarcoma cells spread to other tissues such as the lungs. We have identified spheroid-like structures formed from osteosarcoma cells which we have termed 'Migratory Bodies'. These Migratory Bodies divide, reattach, and express increased gene expression of stem cell markers, suggesting that they contain tumour initiating (cancer stem) cells and are therefore an ideal model for studying how osteosarcoma cells spread to other tissues.

"We have also looked at the effect of secreted factors from two types of bone cells on osteosarcoma cell migration. The data show that when osteosarcoma cells are cultured with factors secreted by osteoclasts (cells that break down bone) and mesenchymal stromal cells (MSCs; cells with the unique ability to develop into specialised cell types), Migratory Body formation is suppressed. Thus, we believe that both MSCs and osteoclasts secrete factors that modulate Migratory Body formation and thus osteosarcoma cell migration. By investigating these findings further, we hope to understand some of the mechanisms that allow osteosarcoma to spread to other tissues."

o The Charity is also part-funding a PhD student at each of Sheffield and Manchester Universities and two at the University of Southampton, with a combined funding of £183,000 over 3 years. All four projects are focussed on Osteosarcoma.

o As an example, Hannah was our first PhD student and based at Southampton University. Osteosarcoma is the most common bone sarcoma in adolescents and has a poor outlook. Novel treatments for this poorly met patient group are clearly needed but their development is hampered by the complexity of the disease and the environment in which it grows. Stephen Beers, Janos Kanczler and Juliet Gray are a team of bone and cancer specialists brought together by funding from Willberry's Research. Hannah is developing 3D models of osteosarcoma to gain a better understanding of the interactions between the osteosarcoma tumour and its surrounding environment. Osteosarcoma is an incredibly complex type of cancer and currently very little is known about the environment in which it grows. With more knowledge, investigations into more effective treatments for osteosarcoma will be possible, improving patient responses.

Trustees' Report

This project focused initially on the drug mifamurtide (also known as Mepact) which is used in patients, but to which not all respond, to understand how this drug works and potentially how to make it work better in more patients. Her PhD is to develop a 3D model of osteosarcoma, which will enable the testing of new drugs and therapies. This is done by using bone from patients who have had hip replacement surgery and inserting osteosarcoma cells into these bone cores. These cores are then positioned to enable blood vessels to interact with the bone, so that osteosarcoma cells remain alive, and the effect of different therapies can be tested.

o Another project at Southampton University, with Belle as a PhD student, is focused on the early detection of osteosarcoma, which is so important, as we are only too aware how quickly this cancer can spread. The project has been using some very advanced imaging techniques to look at the fibres which are present within osteosarcoma and healthy bone biopsies. Belle is looking at whether differences in these bone fibres in diseased versus healthy bone might be early indicators for osteosarcoma and a measure of metastasis. There have been some really good images and findings so far and results of this project should be published soon.

And our PhD project with Manchester University, which started in October 2019, builds on the success of an earlier two-year research grant funded by the charity, Friends of Rosie Children's Cancer Research Fund. In common with the initial project, our project is being led by Dr Katherine Finegan, MRPharmS with Alex, our PhD student. Previous work performed in this lab has found that a protein called ERK5 can promote the progression of osteosarcoma. It has also been found that high levels of the ERK5 protein can increase the chances of chemotherapy resistance and the spread of osteosarcoma around the body. Therefore, higher levels of ERK5 are linked to a reduced chance of survival in patients. Initial evidence has found that, by removing ERK5, tumour cells and immune cells are no longer able to communicate with each other. This is really positive data from this lab group as it is the communication between the tumour cells and the immune cells which allows the cancer to spread around the body. It is currently unknown how this happens, but removing ERK5 has shown to stop the spread of cancer to the lungs in models of the disease which have been used in the lab. It is really important to fully understand how this happens in order to effectively treat osteosarcoma and to develop this treatment for patient use in the future. This project aims to find out exactly how ERK5 works in the progression of osteosarcoma and determine whether removing ERK5 can improve the response to chemotherapy. This is a promising new avenue for the treatment of osteosarcoma.

o In addition, we have a new fully funded PhD project with Kings College London. This is a three-year research project which is taking place under the expert guidance of Professor Agamemnon Grigoriadis. The project is focusing on understanding and preventing the growth of cancer cells in osteosarcoma patients, as well as looking to stop the spread of cancer around the body. The ability of osteosarcoma to metastasise is what makes it so aggressive and therefore focusing the research on this is really important. This project will look at repurposing a pre-existing drug, which is currently used to treat neonatal jaundice, to block the action of HO-1. HO-1 is a factor which is produced by osteosarcoma patients and prevents the activation of the immune system. By 'kick-starting' the immune system into action, the project will assess if the chemotherapy drugs are able to fight the cancer and stop it from moving to other areas of the body.

o The Charity is currently in the process of preparing for the invitation of further project funding requests from the research community, with the aim of awarding more fully funded PhD projects.

Trustees' Report

o In addition, the trustees are excited to confirm that the Charity will be working together with The Bone Cancer Research Trust to offer funding of up to £250,000 (£125,000 funded by each charity) in the 2024/25 academic year to support projects focused on improving outcomes for osteosarcoma patients. Treatment for osteosarcoma has not changed for several decades and still relies on a cocktail of toxic chemotherapies. New, targeted treatments, with less immediate and long-term effects are desperately needed to ensure more patients survive and thrive after treatment. Both charities are committed to drive improvements through the funding of high impact, innovative and collaborative research. Funding will be available to researchers and/or clinicians working in an academic or clinical institution in the UK, however, international collaboration will be encouraged where appropriate. It is anticipated that this collaboration will lead to further research opportunities in future years.

In respect of Willberry's Wishes, the Charity has a small team of volunteers dedicated to helping organise and provide these equestrian-related Wishes. Interest is growing and is expected to continue to do so, as word has spread about how we can help seriously ill people during their darkest times by giving them experiences to look forward to, whilst making memories for all those involved. We share details of some of the vital Wishes we grant, but other recipients understandably wish to keep them private. We are immensely grateful for the continued support of so many people and organisations in the equestrian world, as this is critical in supporting our ability to provide Willberry's Wishes.

Willberry's Wishes helps so many people, not only the Wishee but also their families, and we always have a number of Wishes that we are working on. Willberry's Wishes is about making memories, giving people things to look forward to and to forget what is happening to them even if it is just for a little while. We hope to help lots of people by granting many more Willberry's Wishes.

Financial review

The following section on Financial Review and Future Developments constitutes the Strategic Report for the purposes of the Companies Act 2006 and the trustees confirm that they have complied with the requirements of section 4 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

• In its sixth year of operation, the Charity generated a (deficit)/ surplus of (£5,880) (previous year £6,468), all of which were unrestricted funds.

The Charity's main source of finance is donations, with a significant contribution also being made from the trading subsidiary.

Reserves policy

The Trustees of the Charity have reviewed the Charity's reserves policy in line with the existing commitments and intended future commitments to osteosarcoma research, Willberry's Wishes and estimates of future administration costs. At 31 March 2023, reserves stood at £1,535,357 (£1,541,237 in the previous year) which was substantially more than the amount required to meet these commitments. These funds are held in low-risk deposit accounts with various financial institutions.

As previously highlighted, the Charity has committed to date to expenditure on seven osteosarcoma research projects with a value of £579,608, of which £458,814 has been spent and the balance of £120,794 is committed expenditure over the next 2 years.

The Charity is currently in the process of preparing for the invitation of applications for further project funding requests from the research community, with the aim of awarding more fully funded research projects. It is anticipated that there will be at least 1 new project costing approximately £90,000 (over 3 years) committed to in each of the next 5 years.

Trustees' Report

In addition, as stated above, the Trustees are excited to confirm that the Charity will be working together with The Bone Cancer Research Trust to offer funding of up to £250,000 (£125,000 funded by each charity) in the 2024/25 academic year to support projects focused on improving outcomes for osteosarcoma patients. It is anticipated that this working relationship will directly lead to further research opportunities in future years with the aim of committing to at least one new large (£250,000) project per year.

In addition, the Charity will continue to fund Willberry's Wishes.

Conclusion

The Trustees believe that the Charity has, through the kind and generous help of our supporters and volunteers, raised funds that will provide a public benefit in years to come through the funding of bone cancer research and the provision of Willberry's Wishes.

Structure, governance and management

Nature of governing document

The company is a registered charity, number 1166416, and was incorporated on 29 March 2016. It is governed by the articles and memorandum of association of that date.

The company is limited by guarantee and without a share capital. All Trustees are members of the company and guarantee to contribute to the assets of the company, in the event of it being wound up, such amounts as may be required not exceeding £10.

Our Trustees

The Charity is currently run by 5 trustees, including Hannah's parents (Rachel and James Francis) and her grandmother (June Clothier). The other two Trustees are Ian Peters, former Financial Controller of Hanson plc, General Manager of Hanson Europe and Finance Director of Breedon Aggregates PLC, and Miles Toulson-Clarke, a former Main Board Director of Williams Lea Group and currently UK CEO of Innovation Group and District Commissioner of the Wylye Valley Pony Club. Each of the Trustees gives their time freely, both in their roles as Trustees and carrying out day to day tasks in running the Charity.

Day to day activities of the Charity are delegated to each of the Trustees on a functional basis as follows: Rachel Francis – First point of contact, Willberry's Wishes, fundraising and research, James Francis – Willberry's Wishes, media and communications and research, June Clothier – trading subsidiary sales including online and at events and research, Miles Toulson-Clarke – research and media and communications, Ian Peters – finance and legal.

Induction and training of trustees

Before being appointed, a potential new trustee is encouraged to attend a number of trustee meetings to familiarise themselves with the work of the Charity. A newly appointed trustee receives guidance and informal training to enable them to perform their duties effectively, including governance and management, an induction to the history and current activities of the Charity, code of conduct and charity ethics. New trustees are provided with copies of key documents including the Charity's governing documents, minutes of recent trustees' meetings and, once these are available, the latest set of financial statements and trustees' report.

Trustees' Report

Financial Instruments

Objectives and policies

The Charity's activities expose it to a number of financial risks, principally liquidity. The Charity does not use derivative financial instruments.

Liquidity risk and interest rates

The Charity's principal financial assets are bank balances and cash, trade and other receivables, and investments.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies. The Charity has deliberately taken a conservative approach to investing its available funds during the financial year which, given the current international interest environment, has generated a low rate of return. There is some residual risk to the Charity should interest rates turn negative.

In order to maintain liquidity to ensure that sufficient funds are available for ongoing operations and future developments, the Charity has adopted a conservative reserves policy.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Reference and Administrative Details

Trustees	J S Clothier J R Francis R Francis I A Peters C T M Toulson-Clarke
Charity Registration Number	1166416
Company Registration Number	10089069
	The charity is incorporated in England and Wales.
Registered Office	Manor Farm Hemington Radstock BA3 5XX
Independent Examiner	Paul Giessler FCA Francis Clark LLP Hitchcock House Hilltop Park Devizes Road Salisbury SP3 4UF

The annual report was approved by the trustees of the charity on 5/10/23. and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Statement of trustees' responsibilities

The trustees (who are also the directors of Hannah's Willberry Wonder Pony Charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 5/10/23 and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2023.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the accounts. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the accounts present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of Hannah's Willberry Wonder Pony Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')

.....
Paul Giessler FCA
Francis Clark LLP

Hitchcock House
Hilltop Park
Devizes Road
Salisbury
SP3 4UF

Date: 10 October 2023

Hannah's Willberry Wonder Pony Charity

Statement of Financial Activities for the Year Ended 31 March 2023 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Total 2023 £
Income and Endowments from:			
Donations and legacies	3	91,346	91,346
Investment income	4	12,267	12,267
Total income		103,613	103,613
Expenditure on:			
Charitable activities	5	(109,493)	(109,493)
Total expenditure		(109,493)	(109,493)
Net expenditure		(5,880)	(5,880)
Net movement in funds		(5,880)	(5,880)
Reconciliation of funds			
Total funds brought forward		1,541,237	1,541,237
Total funds carried forward	15	1,535,357	1,535,357

	Note	Unrestricted funds £	Total 2022 £
Income and Endowments from:			
Donations and legacies	3	135,676	135,676
Investment income	4	5,101	5,101
Total income		140,777	140,777
Expenditure on:			
Charitable activities	5	(134,309)	(134,309)
Total expenditure		(134,309)	(134,309)
Net income		6,468	6,468
Net movement in funds		6,468	6,468
Reconciliation of funds			
Total funds brought forward		1,534,769	1,534,769
Total funds carried forward	15	1,541,237	1,541,237

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2022 is shown in note 15.

Hannah's Willberry Wonder Pony Charity

(Registration number: 10089069)
Balance Sheet as at 31 March 2023

	Note	2023 £	2022 £
Fixed assets			
Investments	9	1	1
Current assets			
Debtors	10	12,837	20,121
Cash at bank and in hand	11	1,543,324	1,524,115
		1,556,161	1,544,236
Creditors: Amounts falling due within one year	12	(20,805)	(3,000)
Net current assets		1,535,356	1,541,236
Net assets		1,535,357	1,541,237
Funds of the charity:			
Unrestricted income funds			
Unrestricted funds		1,535,357	1,541,237
Total funds	15	1,535,357	1,541,237

For the financial year ending 31 March 2023 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements on pages 13 to 23 were approved by the trustees, and authorised for issue on 3/10/23 and signed on their behalf by:

.....
I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Statement of Cash Flows for the Year Ended 31 March 2023

	Note	2023 £	2022 £
Cash flows from operating activities			
Net cash (expenditure)/income		(5,880)	6,468
Adjustments to cash flows from non-cash items			
Investment income	4	(12,267)	(5,101)
		(18,147)	1,367
Working capital adjustments			
Decrease in debtors	10	7,284	1,559
Increase/(decrease) in creditors	12	17,805	(9,940)
Net cash flows from operating activities		6,942	(7,014)
Cash flows from investing activities			
Interest receivable and similar income	4	12,267	5,101
Net increase/(decrease) in cash and cash equivalents		19,209	(1,913)
Cash and cash equivalents at 1 April		1,524,115	1,526,028
Cash and cash equivalents at 31 March		1,543,324	1,524,115

All of the cash flows are derived from continuing operations during the above two periods.

Hannah's Willberry Wonder Pony Charity

Notes to the Financial Statements for the Year Ended 31 March 2023

1 Charity status

The charity is limited by guarantee, incorporated in England and Wales, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

The address of its registered office is:
Manor Farm
Hemington
Radstock
BA3 5XX

2 Accounting policies

Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation
Hannah's Willberry Wonder Pony Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern
The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments
All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured. Donations received through third party organisations such as Just Giving are shown net of any fees charged by these organisations.

Expenditure
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grants

Grants are recognised at the amount payable when the intention to make a grant has been communicated to the recipient and the conditions of the grant have been met.

Governance costs
These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Taxation
The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Fixed asset investments
Investments in subsidiaries are stated at historical cost less provision for any diminution in value.

Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Foreign exchange
Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are reported at the rates of exchange prevailing at that date.

The results of overseas operations are translated at the average rates of exchange during the period and their balance sheets at the rates ruling at the balance sheet date. Exchange differences arising on translation of the opening net assets and results of overseas operations are reported in other comprehensive income and accumulated in equity (attributed to non-controlling interests as appropriate).

Other exchange differences are recognised in the Statement of Financial Activities in the period in which they arise except for:

1) exchange differences on transactions entered into to hedge certain foreign currency risks (see above);

2) exchange differences arising on gains or losses on non-monetary items which are recognised in other comprehensive income; and

3) in the case of the consolidated financial statements, exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the foreign operation), which are recognised in other comprehensive income and reported under equity.

Fund structure
Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

3 Income from donations and legacies

	Unrestricted funds General £	Total funds £
Donations and legacies;		
General donations	78,509	78,509
Donation from trading subsidiary	12,837	12,837
Total for 2023	91,346	91,346
Total for 2022	135,676	135,676

4 Investment income

	Unrestricted funds General £	Total funds £
Interest receivable and similar income;		
Interest receivable on bank deposits	12,267	12,267
Total for 2023	12,267	12,267
Total for 2022	5,101	5,101

5 Expenditure on charitable activities

	Note	Unrestricted funds General £	Total funds £
Grant funding of activities		101,000	101,000
Allocated support costs	6	4,280	4,280
Governance costs	6	4,213	4,213
Total for 2023		109,493	109,493
Total for 2022		134,309	134,309

In addition to the expenditure analysed above, there are also governance costs of £4,213 (2022 - £3,643) which relate directly to charitable activities. See note 6 for further details.

6 Analysis of governance and support costs

Charitable activities expenditure

	Unrestricted General £	Total 2023 £	Total 2022 £
Office expenses	1,618	1,618	298
Insurance	545	545	534
Legal and professional fees	-	-	35
Printing, postage and stationary	44	44	418
Bank fees	2,073	2,073	1,872
Governance costs	4,213	4,213	3,643
	8,493	8,493	6,800

Governance costs

	Unrestricted funds General £	Total funds £
Independent examiner fees		
Examination of the financial statements	2,650	2,650
Other fees paid to examiners	1,563	1,563
Total for 2023	4,213	4,213
Total for 2022	3,643	3,643

7 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses from the charity during the year.

8 Independent examiner's remuneration

	2023 £	2022 £
Examination of the financial statements	2,650	2,350
Other fees to examiners		
All other services	1,563	1,293

9 Fixed asset investments

	2023	2022
	£	£
Shares in group undertakings and participating interests	1	1

Details of undertakings

Details of the investments in which the charity holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking	Country of incorporation	Holding	Proportion of voting rights and shares held		Principal activity
			2023	2022	
Subsidiary undertakings					
The Willberry Wonder Pony Trading Company Limited	England and Wales	Ordinary	100%	100%	Sale of merchandise and soft toys branded with Hannah's Willberry Wonder Pony

Subsidiaries

The trading subsidiary company donates its profits to the charity. For the period 1 April 2022 to 31 March 2023, the subsidiary's turnover was £38,602 (2022 - £28,797) and total expenditure was £38,602 (2022 - £28,797).

10 Debtors

	2023	2022
	£	£
Due from group undertakings	12,837	20,121

11 Cash and cash equivalents

	2023	2022
	£	£
Cash at bank	1,543,324	1,524,115

12 Creditors: amounts falling due within one year

	2023	2022
	£	£
Accruals	20,805	3,000

13 Analysis of net assets between funds

	Unrestricted funds General	Total funds at 31 March 2023
	£	£
Fixed asset investments	1	1
Current assets	1,556,161	1,556,161
Current liabilities	(20,805)	(20,805)
Total net assets	1,535,357	1,535,357

	Unrestricted funds General	Total funds at 31 March 2022
	£	£
Fixed asset investments	1	1
Current assets	1,544,236	1,544,236
Current liabilities	(3,000)	(3,000)
Total net assets	1,541,237	1,541,237

14 Related party transactions

The charity has taken advantage of the exemption in Financial Reporting Standards 102 chapter 33 "Related Party Disclosure" and has not disclosed transactions with wholly owned group untertakings.

Donations made by the trustees without any conditions attached totalled £150 (2022 - £575) for the year.

Notes to the Financial Statements for the Year Ended 31 March 2023

15 Funds

	Balance at 1 April 2022 £	Incoming resources £	Resources expended £	Balance at 31 March 2023 £
Unrestricted funds				
General	1,541,237	103,613	(109,493)	1,535,357

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
Unrestricted funds				
General	1,534,769	140,777	(134,309)	1,541,237

Hannah's Willberry Wonder Pony Charity

Detailed Statement of Financial Activities for the Year Ended 31 March 2023

	Total 2023 £	Total 2022 £
Income and Endowments from:		
Donations and legacies (analysed below)	91,346	135,676
Investment income (analysed below)	12,267	5,101
Total income	103,613	140,777
Expenditure on:		
Charitable activities (analysed below)	(109,493)	(134,309)
Total expenditure	(109,493)	(134,309)
Net (expenditure)/income	(5,880)	6,468
Net movement in funds	(5,880)	6,468
Reconciliation of funds		
Total funds brought forward	1,541,237	1,534,769
Total funds carried forward	1,535,357	1,541,237

Hannah's Willberry Wonder Pony Charity

Detailed Statement of Financial Activities for the Year Ended 31 March 2023

	Total 2023 £	Total 2022 £
Donations and legacies		
Donation from Willberry Trading Co	12,837	10,121
Other Donations	78,509	125,555
	91,346	135,676
Investment income		
Interest Received on savings a/c	12,267	5,101
	12,267	5,101
Charitable activities		
Insurance	(545)	(534)
Printing	(44)	(418)
Wishes costs	(8,106)	(1,314)
Project costs	(92,894)	(126,195)
Advertising	(1,618)	(298)
Compliance inc legal	-	(35)
Bank Fees	(2,073)	(1,872)
Independent examiner's remuneration	(2,650)	(2,350)
Other fees paid to independent examiners	(1,563)	(1,293)
	(109,493)	(134,309)

HANNAH'S WILLBERRY WONDER PONY CHARITY

England & Wales - Charity number 1166416

Accounts

Company registration number: 10089069
Charity registration number: 1166416

Hannah's Willberry Wonder Pony Charity

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2022

Hannah's Willberry Wonder Pony Charity

Contents

Trustees' Report	1 to 9
Reference and Administrative Details	7
Independent Examiner's Report	10 to 11
Statement of Financial Activities	12
Balance Sheet	13
Statement of Cash Flows	14
Notes to the Financial Statements	15 to 22

Hannah's Willberry Wonder Pony Charity

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2022.

Objectives and activities

Our purpose

Hannah's Willberry Wonder Pony Charity seeks to provide a public benefit by:

- promoting research into the causes, prevention and treatment of bone cancer and other types of cancer;
- promoting the health and wellbeing of people with a disability or serious illness; or, people who are affected by the disability or serious illness of a close family member; or, people who are suffering from bereavement following the death of a close family member, by providing or assisting in the provision of opportunities to ride or enjoy other equestrian related experiences; and
- assisting in the treatment and care of people suffering from bone cancer and other types of cancer and to help people caring for them.

The Charity can provide:

- grants to organisations carrying out research into bone cancer, provided that the results of the research funded will be published. In the event that the Charity is not the sole funder of any research then the grant of funding will be subject to a condition that results of research will be published and available for general use;
- grants to organisations, individuals and their families to assist those affected by bone cancer and other types of cancer;
- an experience of an equestrian nature via our Willberry's Wishes team, making precious memories to treasure forever.

Background

- Hannah Francis, the founder of the Charity, who tragically passed away on 1 August 2016, wanted to leave a legacy and help people like her who are affected by a serious illness. We the Trustees are grateful to the thousands of people who have helped with donations, fundraising and spreading the word about Hannah's Willberry Wonder Pony Charity.
- When necessary, the Charity engages the services of experts to assist with the running of the Charity but for the vast majority of the time it has been run by volunteers, including the Trustees, and we are very proud of everyone's efforts in keeping the cost of running the Charity to a minimum and thus ensuring maximum funds are available to apply to public benefit. With the current energy crisis impacting many businesses and charities, we are especially grateful to our volunteers for the financial protection they give us by giving many hours of their time, as well as opening their homes for meetings and providing storage space for our trading subsidiary's merchandise stock.

Small companies provision statement

This report has been prepared in accordance with the small companies regime under the Companies Act 2006.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Our activities during 2021/22 and achievements to date

We believe that the Charity has provided a public benefit in the following ways:

• In our sixth full year as a charity we had a surplus of income over expenditure of £6,468 (previous year utilised funds of £20,084) on income of £140,777 (previous year £96,899). This was another successful year in terms of funds generation, with fundraising efforts recovering from the somewhat low level in the previous year that was due to the impact of the Covid pandemic on charity fundraising generally and on equestrian events specifically. We are incredibly grateful for the fabulous fundraising efforts and donations from so many of our supporters. We also received generous donations from individuals, trusts and other charities. The money raised will help to provide funds to meet the Charity's objectives and provide public benefit in the years to come by helping fund bone cancer research and providing Willberry's Wishes.

• The trading subsidiary, which sells Willberry branded merchandise and donates all of its profits (£10,121 in 2021/22, previous year £14,680) to the Charity, has had another successful year. Demand remained steady for our Berry Ponies and for other items which were also sold at equestrian events and online. The portfolio of branded items offered is constantly reviewed to ensure that we keep our followers happy and achieve the best financial outcome.

• During the year, we have provided a number of Willberry's Wishes to people who are fighting, or are affected by, serious illness. Activities earlier in the year were affected by the Covid restrictions but we have adapted and carried on. Spending during the year amounted to £1,314 providing these experiences which included:

o A weekend riding trip in County Mayo, Ireland
o A trip to meet international event rider, Pippa Funnell, with a full tour of her yard
o A series of riding lessons at a local equestrian centre and a trip to the Hannah Francis One Day Event
o A photographic session for owner and her horse
o A trip to meet international event rider, Mary King, followed by lunch with friends by the sea
o A riding lesson with international event rider, Wills Oakden

We are extremely fortunate that many wonderful people in the equestrian community assist us in providing Wishes at no charge to the Charity. Since formation, many Wishes have been granted and all of these have been very well received by the recipients and we look forward to providing many more.

• In respect of medical research, we have in place an expert panel to assist the Trustees in selecting and analysing bone cancer research projects. The expert panel is headed by Dr Claire Clarkin, Associate Professor of Developmental Biology, University of Southampton, and she is very ably assisted by Dr Alice Goring, who completed a PhD related to the study of the role of blood vessels in bone diseases, and they both provide critical assistance to the Charity in managing the medical research investment process. We have continued to meet numerous clinical and academic specialists in the field of Osteosarcoma research and have made significant progress in increasing the profile of the Charity in the academic and scientific communities, including advertising for PhD studentships with major universities.

To date we have identified and committed to 7 projects from leading English Universities that we are supporting with a combined value of up to £579,000, of which £136,135 was spent in the financial year. We are confident that in the coming years we will identify projects from other institutions that will assist in the identification of the causes, prevention and treatment of bone cancer and other types of cancer. The lead time for identifying, reviewing, approving and funding research projects is up to 2 years.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Our Strategy Going Forwards

• The Trustees continue to review the strategy of the Charity to ensure that it provides public benefit and has the ability to meet its objectives. The Trustees are hopeful that income generated in 2022/23 will meet our target of £73,000 and this, together with our strong reserves position, will enable us to carry out the Charity's objectives in future years.

• As mentioned above, the Charity has entered into agreements to fund seven research projects. Due to the impact of Covid-19, several of these projects were partially delayed as access to University laboratory facilities was severely restricted, firstly due to the lockdown itself and then the necessary reduction in capacity to provide a safe environment in which to work and observe social distancing recommendations which occurred post the lockdown. The cost impact of these delays has been minimal.

The projects are listed below:

o The first is with the renowned Department of Oncology and Metabolism at Sheffield University which runs until the end of 2023, with a total cost of up to £227,000. The project can be summarised as follows:

The main current therapeutic approach for osteosarcoma is a combination of chemotherapy drugs associated with surgery. Unfortunately, not all patients respond to these chemotherapy drugs and, in addition, their tumour/s can become 'chemo- resistant' and their overall 5-year survival rate is then drastically reduced. There is clearly a need for alternative, more effective treatments to increase the survival rates of osteosarcoma patients. The project is utilising a technique called 'High throughput screening' of compound libraries to identify whether existing drugs can be used in osteosarcoma. Commercially available compound libraries are being used to enable the rapid screening of over 3,300 drugs. This will provide a substantial opportunity to identify new drug candidates for rapid clinic/patient benefit, as these compounds have already been approved for human use.

The project's focus is on improving the treatment options for osteosarcoma, by looking into using drugs which are already on the market for a different purpose for the treatment of bone cancer. As the drugs being screened have already gone through all the relevant safety tests on humans, re-purposing one of them would massively decrease the time before the drugs were able to be used to treat patients and this would be enormously advantageous due to the limited treatment options currently available. Excitingly, out of the 4,400 drugs which have been screened so far, 550 have been found to have a negative effect on the growth of osteosarcoma cells (growing in a dish) at high doses. Although there is still plenty of work to be done in these early stages of the project, and the drugs must now go through screening at a lower concentration in order to find suitable candidates for further testing, this is a really exciting start!

o Another of our projects is a first fully-funded PhD studentship, based at Middlesex University within the Centre for Investigative & Diagnostic Oncology. The research, led by Dr Helen Roberts (Senior Lecturer), aims to unravel the complex cellular and environmental control of how the rare type of bone cancer the Charity is focused on, osteosarcoma, spreads to other tissues such as the lungs.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

For the past 30 years, survival rates in osteosarcoma patients have remained unchanged, partly due to the lack of research into why the tumour spreads and what initiates this process. Preclinical and clinical evidence highlights that osteosarcoma tumours likely reside in the bone environment due to 'protective' interactions with bone cells. It is hypothesised that disruption of these protective interactions causes the tumour to move from the bone to the lungs in a process called metastasis. The project is investigating why osteosarcoma tumours metastasise to the lungs and is using cutting edge cell-based assays to define not only the role of the bone cells, but also the lung environment. The project draws on the tissue engineering experience of Dr Scott Roberts (Senior Lecturer in Translational Skeletal Research, RVC), who has spent over a decade developing laboratory grown tissues that can be used for regenerative medicine and the investigation of disease processes.

o The Charity is also part-funding a PhD student at each of Sheffield and Manchester Universities and two at the University of Southampton, with a combined funding of £183,000 over 3 years. All four projects are focussed on Osteosarcoma. As an example, Hannah was our first PhD student and is based at Southampton University, under the supervision of Professor Steve Beers. Her PhD is to develop a 3D model of osteosarcoma, which will enable the testing of new drugs and therapies. This is done by using bone from patients who have had hip replacement surgery and inserting osteosarcoma cells into these bone cores. These cores are then positioned to enable blood vessels to interact with the bone, so that osteosarcoma cells remain alive, and the effect of different therapies can be tested. Her first year has been spent successfully optimising this novel model of osteosarcoma.

Another project at Southampton University, with Belle as a PhD student, is focused on the early detection of osteosarcoma, which is so important, as we are only too aware how quickly this cancer can spread. The project has been using some very advanced imaging techniques to look at the fibres which are present within osteosarcoma and healthy bone biopsies. Belle is looking at whether differences in these bone fibres in diseased versus healthy bone might be early indicators for osteosarcoma and a measure of metastasis. There have been some really good images and findings so far and results of this project should be published soon.

And our PhD project with Manchester University, which started in October 2019, builds on the success of an earlier two-year research grant funded by the charity, Friends of Rosie Children's Cancer Research Fund. In common with the initial project, our project is being led by Dr Katherine Finegan, MRPharmS. During the initial project, Dr Finegan's team found that a protein, called ERK5, can control the growth and spread of osteosarcomas. By removing ERK5, they were able to slow the growth of osteosarcomas and prevent their spread to the lung (metastases). The PhD being part-funded by Hannah's Willberry Wonder Pony Charity builds on these exciting preliminary findings to explore exactly how ERK5 controls osteosarcoma progression.

o In addition, we have a new fully funded PhD project with Kings College London. This is a three-year research project which will take place under the expert guidance of Professor Agamemnon Grigoriadis. The project will focus on understanding and preventing the growth of cancer cells in osteosarcoma patients, as well as looking to stop the spread of cancer around the body. The ability of osteosarcoma to metastasise is what makes it so aggressive and therefore focusing the research on this is really important. This project will look at repurposing a pre-existing drug, which is currently used to treat neonatal jaundice, to block the action of HO-1. HO-1 is a factor which is produced by osteosarcoma patients and prevents the activation of the immune system. By 'kick-starting' the immune system into action, the project will assess if the chemotherapy drugs are able to fight the cancer and stop it from moving to other areas of the body.

Trustees' Report

o The Charity is currently in the process of preparing for the invitation of further project funding requests from the research community, with the aim of awarding more fully funded PhD projects. The trustees are also examining the potential for some jointly funded research projects with other charities in the bone cancer space, as we believe there is merit in combining our research efforts to maximise progress.

• In respect of Willberry's Wishes, the Charity has a small team of volunteers dedicated to helping organise and provide these equestrian-related Wishes. Interest is growing and is expected to continue to do so, as word has spread about how we can help seriously ill people during their darkest times by giving them experiences to look forward to, whilst making memories for all those involved. We share details of some of the vital Wishes we grant, but other recipients understandably wish to keep them private. We are immensely grateful for the continued support of so many people and organisations in the equestrian world, as this is critical in supporting our ability to provide Willberry's Wishes.

• Willberry's Wishes helps so many people, not only the Wishee but also their families, and we always have a number of Wishes that we are working on. For example:

o One lady has always wanted to ride her horse on the gallops at Newmarket and we are working with the Jockey Club to see if we can make her wish extra special with a tour and a delicious lunch with her very dear friend.
o We are hoping to help a little girl with a brain tumour who tragically has a terminal prognosis. She is just 6 years old and would like to ride a pony and feed them apples. Hannah's miniature Shetland pony, Doris, is going to get her friend, Teddy (another adorable miniature Shetland), over to the farm for a special visit. We are planning lots of pony cuddles, grooming, riding, meeting the other farm animals, a picnic and a special photographer to capture the day so that we can make up a photo memory book that they will have forever.

• Willberry's Wishes is about making memories, giving people things to look forward to and to forget what is happening to them even if it is just for a little while. We hope to help lots of people by granting many more Willberry's Wishes.

Financial review

The following section on Financial Review and Future Developments constitutes the Strategic Report for the purposes of the Companies Act 2006 and the trustees confirm that they have complied with the requirements of section 4 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

• In its sixth year of operation, the Charity generated a surplus of £6,468 (previous year net expenditure of £20,084), all of which were unrestricted funds.

The Charity's main source of finance is donations, with a good contribution also being made from the trading subsidiary.

Reserves policy

The Charity's policy is to maintain minimum reserves of £25,000, which represents approximately 12 months of administration costs. At 31 March 2022, reserves stood at £1,541,237 (£1,534,769 in the previous year) which was substantially more than the minimum amount. These funds are held in low risk deposit accounts with various financial institutions.

As previously highlighted, the Charity has committed to date to expenditure on seven Osteosarcoma research projects of up to £579,000, of which approximately £210,000 is committed over the next 3 years.

Trustees' Report

The Charity is currently in the process of preparing for the invitation of applications for further project funding requests from the research community, with the aim of awarding more fully funded PhD projects. The trustees are also examining the potential for some jointly funded research projects with other charities in the bone cancer research space, as we believe there is merit in combining our research efforts and appealing to a wider audience in order to maximise progress utilising available reserves.

In addition the Charity will continue to fund Willberry's Wishes.

Conclusion

The Trustees believe that the Charity has, through the kind help of our supporters and volunteers, raised funds that will provide a public benefit in years to come through the funding of bone cancer research and the provision of Willberry's Wishes.

Structure, governance and management

Nature of governing document

The company is a registered charity, number 1166416, and was incorporated on 29 March 2016. It is governed by the articles and memorandum of association of that date.

The company is limited by guarantee and without a share capital. All Trustees are members of the company and guarantee to contribute to the assets of the company, in the event of it being wound up, such amounts as may be required not exceeding £10.

Our Trustees

The Charity is currently run by 5 Trustees, including Hannah's parents (Rachel and James Francis) and her Grandmother (June Clothier). The other two Trustees are Ian Peters, former Financial Controller of Hanson plc, General Manager of Hanson Europe and Finance Director of Breedon Aggregates and Miles Toulson-Clarke, a former Main Board Director of Williams Lea Group and currently UK CEO of Innovation Group and District Commissioner of the Wylye Valley Pony Club. Each of the Trustees gives their time freely both in their roles as Trustees and carrying out day to day tasks in running the Charity.

Day to day activities of the Charity are delegated to each of the Trustees on a functional basis as follows: Rachel Francis – First point of contact, Willberry's Wishes, fundraising and research, James Francis – Willberry's Wishes, media and communications and research, June Clothier – trading subsidiary sales including online and at events and research, Miles Toulson-Clarke – research and media and communications, Ian Peters – finance and legal.

Induction and training of trustees

Before being appointed, a potential new trustee is encouraged to attend a number of trustee meetings to familiarise themselves with the work of the Charity. A newly appointed trustee receives guidance and informal training to enable them to perform their duties effectively, including governance and management, an induction to the history and current activities of the Charity, code of conduct and charity ethics. New trustees are provided with copies of key documents including the Charity's governing documents, minutes of recent trustees meetings and, once these are available, the latest set of financial statements and trustees' report.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Reference and Administrative Details

Trustees	J S Clothier
	J R Francis
	R Francis
	I A Peters
	C T M Toulson-Clarke
Charity Registration Number	1166416
Company Registration Number	10089069
	The charity is incorporated in England and Wales.
Registered Office	Manor Farm Hemington Radstock BA3 5XX
Independent Examiner	Paul Giessler FCA Francis Clark LLP Hitchcock House Hilltop Park Devizes Road Salisbury SP3 4UF

Financial Instruments

Objectives and policies

The Charity's activities expose it to a number of financial risks, principally liquidity. The Charity does not use derivative financial instruments.

Liquidity risk and interest rates

• Liquidity risk and interest rates
• The Charity's principal financial assets are bank balances and cash, trade and other receivables, and investments.

• The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies. The Charity has deliberately taken a conservative approach to investing its available funds during the course of the financial year which, given the current international interest environment, has generated a low rate of return. There is some residual risk to the Charity should interest rates turn negative.

• In order to maintain liquidity to ensure that sufficient funds are available for ongoing operations and future developments, the Charity has adopted a conservative reserves policy.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

The annual report was approved by the trustees of the charity on 15/11/22 and signed on its behalf by:

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Statement of trustees' responsibilities

The trustees (who are also the directors of Hannah's Willberry Wonder Pony Charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". The report and accounts have been prepared in accordance with the provisions in the Companies Act 2006 relating to small companies.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 15/11/22 and signed on its behalf by:

.....
I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the accounts. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the accounts present a 'true and fair' view and my report is limited to those specific matters set out in the independent examiner's statement.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of Hannah's Willberry Wonder Pony Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity ('the Company')



.....
Paul Giessler FCA
Francis Clark LLP

Hitchcock House
Hilltop Park
Devizes Road
Salisbury
SP3 4UF

Date:.....17 November 2022

Hannah's Willberry Wonder Pony Charity

Statement of Financial Activities for the Year Ended 31 March 2022 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Total 2022 £
Income and Endowments from:			
Donations and legacies	3	135,676	135,676
Investment income	4	5,101	5,101
Total income		140,777	140,777
Expenditure on:			
Charitable activities	5	(134,309)	(134,309)
Total expenditure		(134,309)	(134,309)
Net income		6,468	6,468
Net movement in funds		6,468	6,468
Reconciliation of funds			
Total funds brought forward		1,534,769	1,534,769
Total funds carried forward	15	1,541,237	1,541,237

	Note	Unrestricted funds £	Total 2021 £
Income and Endowments from:			
Donations and legacies	3	91,396	91,396
Investment income	4	5,503	5,503
Total income		96,899	96,899
Expenditure on:			
Charitable activities	5	(116,983)	(116,983)
Total expenditure		(116,983)	(116,983)
Net expenditure		(20,084)	(20,084)
Net movement in funds		(20,084)	(20,084)
Reconciliation of funds			
Total funds brought forward		1,554,853	1,554,853
Total funds carried forward	15	1,534,769	1,534,769

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2021 is shown in note 15.

Hannah's Willberry Wonder Pony Charity

(Registration number: 10089069)
Balance Sheet as at 31 March 2022

	Note	2022 £	2021 £
Fixed assets			
Investments	9	1	1
Current assets			
Debtors	10	20,121	21,680
Cash at bank and in hand	11	1,524,115	1,526,028
		1,544,236	1,547,708
Creditors: Amounts falling due within one year	12	(3,000)	(12,940)
Net current assets		1,541,236	1,534,768
Net assets		1,541,237	1,534,769
Funds of the charity:			
Unrestricted income funds			
Unrestricted funds		1,541,237	1,534,769
Total funds	15	1,541,237	1,534,769

For the financial year ending 31 March 2022 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The financial statements on pages 12 to 22 were approved by the trustees, and authorised for issue on ..15/11/22.. and signed on their behalf by:

.....
I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Statement of Cash Flows for the Year Ended 31 March 2022

	Note	2022 £	2021 £
Cash flows from operating activities			
Net cash income/(expenditure)		6,468	(20,084)
Adjustments to cash flows from non-cash items			
Investment income	4	(5,101)	(5,503)
		1,367	(25,587)
Working capital adjustments			
Decrease in debtors	10	1,559	13,631
(Decrease)/increase in creditors	12	(9,940)	9,940
Net cash flows from operating activities		(7,014)	(2,016)
Cash flows from investing activities			
Interest receivable and similar income	4	5,101	5,503
Net (decrease)/increase in cash and cash equivalents		(1,913)	3,487
Cash and cash equivalents at 1 April		1,526,028	1,522,541
Cash and cash equivalents at 31 March		1,524,115	1,526,028

All of the cash flows are derived from continuing operations during the above two periods.

Hannah's Willberry Wonder Pony Charity

Notes to the Financial Statements for the Year Ended 31 March 2022

1 Charity status

The charity is limited by guarantee, incorporated in England and Wales, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

The address of its registered office is:
Manor Farm
Hemington
Radstock
BA3 5XX

2 Accounting policies

Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation
Hannah's Willberry Wonder Pony Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern
The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments
All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured. Donations received through third party organisations such as Just Giving are shown net of any fees charged by these organisations.

Expenditure
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grants

Grants are recognised at the amount payable when the intention to make a grant has been communicated to the recipient and the conditions of the grant have been met.

Governance costs
These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Taxation
The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Fixed asset investments
Investments in subsidiaries are stated at historical cost less provision for any diminution in value.

Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Foreign exchange
Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are reported at the rates of exchange prevailing at that date.

The results of overseas operations are translated at the average rates of exchange during the period and their balance sheets at the rates ruling at the balance sheet date. Exchange differences arising on translation of the opening net assets and results of overseas operations are reported in other comprehensive income and accumulated in equity (attributed to non-controlling interests as appropriate).

Other exchange differences are recognised in the Statement of Financial Activities in the period in which they arise except for:

1) exchange differences on transactions entered into to hedge certain foreign currency risks (see above);

2) exchange differences arising on gains or losses on non-monetary items which are recognised in other comprehensive income; and

3) in the case of the consolidated financial statements, exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the foreign operation), which are recognised in other comprehensive income and reported under equity.

Fund structure
Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

3 Income from donations and legacies

	Unrestricted funds General £	Total funds £
Donations and legacies;		
General donations	125,555	125,555
Donation from trading subsidiary	10,121	10,121
Total for 2022	135,676	135,676
Total for 2021	91,396	91,396

4 Investment income

	Unrestricted funds General £	Total funds £
Interest receivable and similar income;		
Interest receivable on bank deposits	5,101	5,101
Total for 2022	5,101	5,101
Total for 2021	5,503	5,503

5 Expenditure on charitable activities

	Note	Unrestricted funds General £	Total funds £
Grant funding of activities		127,509	127,509
Allocated support costs	6	3,157	3,157
Governance costs	6	3,643	3,643
Total for 2022		134,309	134,309
Total for 2021		116,983	116,983

In addition to the expenditure analysed above, there are also governance costs of £3,643 (2021 - £3,553) which relate directly to charitable activities. See note 6 for further details.

6 Analysis of governance and support costs

Charitable activities expenditure

	Unrestricted General £	Total 2022 £	Total 2021 £
Office expenses	298	298	1,156
Insurance	534	534	542
Legal and professional fees	35	35	35
Printing, postage and stationary	418	418	49
Bank fees	1,872	1,872	-
Governance costs	3,643	3,643	3,553
	6,800	6,800	5,335

Governance costs

	Unrestricted funds General £	Total funds £
Independent examiner fees		
Examination of the financial statements	2,350	2,350
Other fees paid to examiners	1,293	1,293
Total for 2022	3,643	3,643
Total for 2021	3,553	3,553

7 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses from the charity during the year.

8 Independent examiner's remuneration

	2022 £	2021 £
Examination of the financial statements	2,350	2,250
Other fees to examiners		
All other services	1,293	1,303

9 Fixed asset investments

	2022	2021
	£	£
Shares in group undertakings and participating interests	1	1

Details of undertakings

Details of the investments in which the charity holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking	Country of incorporation	Holding	Proportion of voting rights and shares held		Principal activity
			2022	2021	
Subsidiary undertakings					
The Willberry Wonder Pony Trading Company Limited	England and Wales	Ordinary	100%	100%	Sale of merchandise and soft toys branded with Hannah's Willberry Wonder Pony

Subsidiaries

The trading subsidiary company donates its profits to the charity. For the period 1 April 2021 to 31 March 2022, the subsidiary's turnover was £28,797 (2021 - £31,298) and total expenditure was £28,797 (2021 - £31,298).

10 Debtors

	2022	2021
	£	£
Due from group undertakings	20,121	21,680

11 Cash and cash equivalents

	2022	2021
	£	£
Cash at bank	1,524,115	1,526,028

12 Creditors: amounts falling due within one year

	2022	2021
	£	£
Accruals	3,000	12,940

13 Analysis of net assets between funds

	Unrestricted funds General	Total funds at 31 March 2022
	£	£
Fixed asset investments	1	1
Current assets	1,544,236	1,544,236
Current liabilities	(3,000)	(3,000)
Total net assets	1,541,237	1,541,237

	Unrestricted funds General	Total funds at 31 March 2021
	£	£
Fixed asset investments	1	1
Current assets	1,547,708	1,547,708
Current liabilities	(12,940)	(12,940)
Total net assets	1,534,769	1,534,769

14 Related party transactions

The charity has taken advantage of the exemption in Financial Reporting Standards 102 chapter 33 "Related Party Disclosure" and has not disclosed transactions with wholly owned group untertakings.

Donations made by the trustees without any conditions attached totalled £575 (2021 - £2,100) for the year.

Notes to the Financial Statements for the Year Ended 31 March 2022

15 Funds

	Balance at 1 April 2021 £	Incoming resources £	Resources expended £	Balance at 31 March 2022 £
Unrestricted funds				
General	1,534,769	140,777	(134,309)	1,541,237

	Balance at 1 April 2020 £	Incoming resources £	Resources expended £	Balance at 31 March 2021 £
Unrestricted funds				
General	1,554,853	96,899	(116,983)	1,534,769

HANNAH'S WILLBERRY WONDER PONY CHARITY

England & Wales - Charity number 1166416

Accounts

Hannah's Willberry Wonder Pony Charity

(A company limited by guarantee)

Annual Report and Financial Statements
Year Ended 31 March 2021

Company registration number: 10089069

Charity registration number: 1166416

Hannah's Willberry Wonder Pony Charity

Contents

Trustees' Report	1 to 7
Reference and Administrative Details	7
Statement of Trustees' Responsibilities	8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Statement of Cash Flows	12
Notes to the Financial Statements	13 to 19

Hannah's Willberry Wonder Pony Charity

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2021.

Objectives and Activities

Our Purpose

Hannah's Willberry Wonder Pony Charity seeks to provide a public benefit by:

- promoting research into the causes, prevention and treatment of bone cancer and other types of cancer
- promoting the health and wellbeing of people with a disability or serious illness; or, people who are affected by the disability or serious illness of a close family member; or, people who are suffering from bereavement following the death of a close family member, by providing or assisting in the provision of opportunities to ride or enjoy other equestrian related experiences; and
- assisting in the treatment and care of people suffering from bone cancer and other types of cancer and to help people caring for them.

The Charity can provide:

- grants to organisations carrying out research into bone cancer, provided that the results of the research funded will be published. In the event that the Charity is not the sole funder of any research then the grant of funding will be subject to a condition that results of research will be published and available for general use
- grants to organisations, individuals and their families to assist those affected by bone cancer and other types of cancer
- an experience of an equestrian nature via our Willberry's Wishes team, making precious memories to treasure forever.

Background

- Hannah Francis, the founder of the Charity, who tragically passed away on 1 August 2016, wanted to leave a legacy and help people like her who are affected by a serious illness. We the Trustees are grateful to the thousands of people who have helped with donations, fundraising and spreading the word about Hannah's Willberry Wonder Pony Charity.
- When necessary, the Charity engages the services of experts to assist with the running of the Charity but for the vast majority of the time it has been run by volunteers, including the Trustees, and we are very proud of everyone's efforts in keeping the cost of running the Charity to a minimum and thus ensuring maximum funds are available to apply to public benefit. Our volunteers have given many hours of their time, as well as opening their homes for meetings and providing storage space for our trading subsidiary's merchandise stock.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Our Activities During 2020/21 and Achievements to Date

We believe that the Charity has provided a public benefit in the following ways:

- In our fifth full year as a charity we have utilised funds of £20,084 (previous year surplus £78,421) on income of £96,899 (previous year £190,830). This was another successful year in terms of funds generation, albeit at lower levels than previous years due to the impact of the Covid pandemic on equestrian events during the year which meant that supporters fundraising activities and sales of Willberry merchandise were curtailed. We are most grateful for the fabulous fundraising efforts and donations from so many of our supporters. We also received generous donations from individuals, trusts and other charities. The money raised will help to provide funds to meet the Charity's objectives and provide public benefit in the years to come by helping fund bone cancer research and providing Willberry's Wishes.
- The trading subsidiary, which sells Willberry branded merchandise and donates all of its profits (£14,680 in 2020/21, previous year £35,311) to the Charity, has had another good year. Demand remained steady for our Berry Ponies and for other items which were also sold at equestrian events and online, albeit sales levels were lower than some previous years as the number of equestrian events actually taking place was lower due to Covid restrictions.
- During the year we have provided a number of Willberry's Wishes to people who are fighting, or are affected by, serious illness. Activities have been affected by the Covid restrictions but we have adapted and carried on. Spending during the year amounted to £1,237 (previous year £3,280) providing these experiences which included;
    - A visit to meet Pippa Funnell at her eventing yard
    - A visit to Kitty King and her eventing yard
    - A photoshoot of a horse and her proud owner
    - A beautiful painting by the talented artist, Amy Goodman

  We are extremely fortunate that many wonderful people in the equestrian community assist us in providing Wishes at no charge to the Charity. Since formation many Wishes have been granted and all of these have been very well received by the recipients and we look forward to providing many more.
- During the year, we have also helped fund the Happiness Horse Box through a donation of £12,000. The Happiness Horsebox will enable people with life- changing injuries and serious illnesses to ride and be with horses. It is an innovative mobile service, a horsebox with a unique design, creating a private meeting space for equine visits to care homes and hospices.It has a hydraulic lifting platform for easy wheelchair access which also enables riders to mount easily and then they can be escorted on special rides in the countryside. It has been designed to have bio-security features to ensure it can work within Covid 19 guidelines.
- In respect of medical research we have in place an expert panel to assist the Trustees in selecting and analysing bone cancer research projects. The expert panel is headed by Dr Claire Clarkin, Associate Professor of Developmental Biology, University of Southampton, and she is very ably assisted by Dr Alice Goring, who completed a PhD related to the study of the role of blood vessels in bone diseases, and they both provide critical assistance to the Charity in managing the medical research investment process. We have continued to meet numerous clinical and academic specialists in the field of Osteosarcoma research and have made significant progress in increasing the profile of the Charity in the academic and scientific communities, including advertising for PhD studentships with major universities.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

To date we have identified and committed to 7 projects from leading English Universities that we are supporting with a combined value of up to £579,000, of which £98,411 was spent in the financial year. We are confident that in the coming years we will identify projects from other institutions that will assist in the identification of the causes, prevention and treatment of bone cancer and other types of cancer. The lead time for identifying, reviewing, approving and funding research projects is up to 2 years.

Our Strategy Going Forwards

The Trustees continue to review the strategy of the Charity to ensure that it provides public benefit and has the ability to meet its objectives. The Trustees are hopeful that income generated in 2021/22 will meet our target of £71,000 and this, together with our strong reserves position, will enable us to carry out the Charity's objectives in future years. This income target is significantly lower than previous years which reflects the impact that Covid-19 has had on the charity sector generally and our charity in particular, where a lot of our funds raised come from horse shows and events and other activities that have been curtailed in 2021.

As mentioned above, the Charity has entered into agreements to fund seven research projects. Due to the impact of Covid-19, several of these projects have been partially delayed as access to University laboratory facilities has been severely restricted, firstly due to the lockdown and post the lockdown the reduction in capacity in order to provide a safe environment in which to work and observe social distancing recommendations. The anticipated cost impact is expected to be minimal, with project end dates extended at limited additional cost to the Charity.

The projects are listed below:

o The first is with the renowned Department of Oncology and Metabolism at Sheffield University which runs until 2023 with a total cost of up to £227,000. The project can be summarised as follows:

- The main current therapeutic approach for osteosarcoma is a combination of chemotherapy drugs associated with surgery. Unfortunately, not all patients respond to these chemotherapy drugs and, in addition, their tumour can become 'chemo- resistant' and their overall 5-year survival rate is then drastically reduced. There is clearly a need for alternative, more effective treatments to increase the survival rates of osteosarcoma patients. The project is utilising a technique called 'High throughput screening" of compound libraries to identify whether existing drugs can be used in osteosarcoma. Commercially available compound libraries are being used to enable the rapid screening of over 3300 drugs. This will provide a substantial opportunity to identify new drug candidates for rapid clinic/patient benefit as these compounds have already been approved for human use.

- The project's focus is on improving the treatment options for osteosarcoma, by looking into using drugs which are already on the market for a different purpose for the treatment of bone cancer. As the drugs being screened have already gone through all the relevant safety tests on humans, re-purposing one of them would massively decrease the time in which the drugs were able to be used to treat patients and this would be enormously advantageous due to the limited treatment options currently available. Excitingly, out of the 4,400 drugs which have been screened so far, 550 have been found to have a negative effect on the growth of osteosarcoma cells (growing in a dish) at high doses. Although there is still plenty of work to be done in these early stages of the project, and the drugs must now go through screening at a lower concentration in order to find suitable candidates for further testing, this is a really exciting start!

Trustees' Report

o The Charity has also agreed the part-funding of a PhD student at each of Sheffield and Manchester Universities and two at the University of Southampton, with a combined funding of £183,000 over 3 years. All four projects are focussed on Osteosarcoma. As an example, Hannah was our first PhD student and is based at Southampton University, under the supervision of Professor Steve Beers. Her PhD is to develop a 3D model of osteosarcoma, which will enable the testing of new drugs and therapies. This is done by using bone from patients who have had hip replacement surgery and inserting osteosarcoma cells into these bone cores. These cores are then inserted into a chick egg - enabling blood vessels to interact with the bone, so that osteosarcoma cells remain alive and the effect of different therapies can be tested. Her first year has been spent successfully optimising this novel model of osteosarcoma.

o During the financial year the Charity has agreed to fully fund two further PhD projects with a combined value of up £169,000 over 3 years. The first of these with Middlesex University aims to look at why osteosarcoma tumours reside in the bone environment, likely due to 'protective' interactions with bone cells and it is hypothesised that disruption of these protective interactions causes the tumour to move from the bone to the lungs in a process called metastasis. It is planned that along with collaborators at the Royal Veterinary College (RVC; University of London), to use cutting edge cell-based assays to define not only the role of the bone cells, but also the lung environment. The project will draw on the tissue engineering experience of Dr Scott Roberts (Senior Lecturer in Translational Skeletal Research, RVC) who has spent over a decade developing laboratory grown tissues that can be used for regenerative medicine and the investigation of disease processes. The intention of the project is to try and identify drug targets that specifically supress tumour metastasis.

• In respect of Willberry's Wishes, the Charity has a small team of volunteers dedicated to helping organise and provide these equestrian-related Wishes. Interest is growing and is expected to continue to do so, as word has spread abouthow we can help seriously ill people during their darkest times by giving them events to look forward to whilst making memories for all of those involved. We share details of some of the fun experiences people are having and we are so grateful for the continued support in the equestrian world from people and organisations that are willing to provide exciting opportunities.

Financial review

The following section on Financial Review and Future Developments constitutes the Strategic Report for the purposes of the Companies Act 2006 and the trustees confirm that they have complied with the requirements of section 4 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

- In its fifth year of operations the Charity made net expenditure of £20,084 (previous year surplus of £78,781) all of which was from unrestricted funds.The Charity's main source of finance is donations, with a significant contribution also being made from the trading subsidiary.

Reserves policy

The Charity's policy is to maintain minimum reserves of £25,000 which represents approximately 12 months of administration costs. At 31 March 2021, reserves stood at £1,534,769 (£1,554,493 in the previous year) which was substantially more than the minimum amount. These funds are held in low risk deposit accounts with various financial institutions.

As previously highlighted, the Charity has committed to expenditure on seven Osteosarcoma research projects of up to £579,000, of which approximately £346,000 is committed over the next 3 years, and it is anticipated that additional grant applications will be received from various institutions in the coming years as awareness of our Charity's activities increases in the medical research community. In addition we will continue to fund Willberry's Wishes.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Conclusion

The Trustees believe that the Charity has, through the kind help of our supporters and volunteers, raised funds that will provide a public benefit in years to come through the funding of bone cancer research and the provision of Willberry's Wishes.

The Trustees believe that the Charity has, through the kind help of our supporters and volunteers, raised funds that will provide a public benefit in years to come through the funding of bone cancer research and the provision of Willberry's Wishes.

Structure, governance and management

Nature of Governing Document

The company is a registered charity, number 1166416, and was incorporated on 29 March 2016. It is governed by the articles and memorandum of association of that date.

The company is limited by guarantee and without a share capital. All Trustees are members of the company and guarantee to contribute to the assets of the company, in the event of it being wound up, such amounts as may be required not exceeding £10.

Our Trustees

• The Charity is currently run by 5 Trustees, including Hannah's parents (Rachel and James Francis) and her Grandmother (June Clothier). The other two Trustees are Ian Peters, former Financial Controller of Hanson plc, General Manager of Hanson Europe and Finance Director of Breedon Aggregates and Miles Toulson-Clarke, a former Main Board Director of Williams Lea Group and currently UK CEO of Innovation Group and District Commissioner of the Wylye Valley Pony Club. Each of the Trustees gives their time freely both in their roles as Trustees and carrying out day to day tasks in running the Charity.

• Day to day activities of the Charity are delegated to each of the Trustees on a functional basis as follows: Rachel Francis - First point of contact, Willberry's Wishes, fundraising and research, James Francis - Willberry's Wishes, media and communications and research, June Clothier - trading subsidiary sales including online and at events and research, Miles Toulson-Clarke - research and media and communications, Ian Peters - finance and legal.

Recruitment and induction of new trustees

Before being appointed, a potential new trustee is encouraged to attend a number of trustee meetings to familiarise themselves with the work of the Charity. A newly appointed trustee receives guidance and informal training to enable them to perform their duties effectively, including governance and management, an induction to the history and current activities of the Charity, code of conduct and charity ethics. New trustees are provided with copies of key documents including the Charity's governing documents, minutes of recent trustees meetings and, once these are available, the latest set of financial statements and trustees' report.

Trustees' Report

Financial Instruments

• The Charity's activities expose it to a number of financial risks, principally liquidity. The Charity does not use derivative financial instruments.

Liquidity risk and Interest rates:

• The Charity's principal financial assets are bank balances and cash, trade and other receivables, and investments.

• The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies. The Charity has deliberately taken a conservative approach to investing its available funds during the course of the financial year which given the current international interest environment has generated a low rate of return. There is some residual risk to the Charity should interest rates turn negative.

• In order to maintain liquidity to ensure that sufficient funds are available for ongoing operations and future developments, the Charity has adopted a conservative reserves policy.

Hannah's Willberry Wonder Pony Charity

Trustees' Report

Reference and Administrative Details

Trustees	J S Clothier J R Francis R Francis I A Peters C T M Toulson-Clarke
Principal Office	Manor Farm Hemington Radstock BA3 5XX The charity is incorporated in England and Wales.
Company Registration Number	10089069
Charity Registration Number	1166416
Independent Examiner	Paul Giessler FCA Francis Clark LLP Hitchcock House Hilltop Park Devizes Road Salisbury SP3 4UF

The annual report was approved by the trustees of the charity on 30/11/21 and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Statement of Trustees' Responsibilities

The trustees (who are also the directors of Hannah's Willberry Wonder Pony Charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on 30/11/21 and signed on its behalf by:

.....

I A Peters
Trustee

Hannah's Willberry Wonder Pony Charity

Independent Examiner's Report to the trustees of Hannah's Willberry Wonder Pony Charity

I report on the accounts of the charity for the year ended 31 March 2021 which are set out on pages 10 to 19 .

Respective responsibilities of trustees and examiner
The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.
Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report
My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement
In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

.....
Paul Giessler FCA
Francis Clark LLP

Hitchcock House
Hilltop Park
Devizes Road
Salisbury
SP3 4UF

Date: 3 December 2021

Hannah's Willberry Wonder Pony Charity

Statement of Financial Activities

Year Ended 31 March 2021
(Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Total 2021 £
Income and Endowments from:			
Donations and legacies	3	91,396	91,396
Investment income	4	5,503	5,503
Total Income		96,899	96,899
Expenditure on:			
Charitable activities	5	(116,983)	(116,983)
Total Expenditure		(116,983)	(116,983)
Net expenditure		(20,084)	(20,084)
Net movement in funds		(20,084)	(20,084)
Reconciliation of funds			
Total funds brought forward		1,554,853	1,554,853
Total funds carried forward	12	1,534,769	1,534,769

	Note	Unrestricted funds £	Total 2020 £
Income and Endowments from:			
Donations and legacies	3	183,333	183,333
Investment income	4	7,497	7,497
Total Income		190,830	190,830
Expenditure on:			
Charitable activities	5	(112,049)	(112,049)
Total Expenditure		(112,049)	(112,049)
Net income		78,781	78,781
Net movement in funds		78,781	78,781
Reconciliation of funds			
Total funds brought forward		1,476,072	1,476,072
Total funds carried forward	12	1,554,853	1,554,853

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2020 is shown in note 12.

Hannah's Willberry Wonder Pony Charity

Balance Sheet

31 March 2021

	Note	2021 £	2020 £
Fixed assets			
Investments	9	1	1
Current assets			
Debtors	10	21,680	35,311
Cash at bank and in hand		1,526,028	1,522,541
		1,547,708	1,557,852
Creditors: Amounts falling due within one year	11	(12,940)	(3,000)
Net current assets		1,534,768	1,554,852
Net assets		1,534,769	1,554,853
Funds of the charity:			
Unrestricted income funds			
Unrestricted funds		1,534,769	1,554,853
Total funds	12	1,534,769	1,554,853

For the financial year ending 31 March 2021 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 10 to 19 were approved by the trustees, and authorised for issue on 30.11.21. and signed on their behalf by:

.....

I A Peters
Trustee

Company Registration Number: 10089069

Hannah's Willberry Wonder Pony Charity

Statement of Cash Flows

Year Ended 31 March 2021

	Note	2021 £	2020 £
Cash flows from operating activities			
Net cash (expenditure)/income		(20,084)	78,781
Adjustments to cash flows from non-cash items			
Investment income	4	(5,503)	(7,497)
		(25,587)	71,284
Working capital adjustments			
Decrease/(increase) in debtors	10	13,631	(83)
Increase in creditors	11	9,940	-
Net cash flows from operating activities		(2,016)	71,201
Cash flows from investing activities			
Interest receivable and similar income	4	5,503	7,497
Net increase in cash and cash equivalents		3,487	78,698
Cash and cash equivalents at 1 April		1,522,541	1,443,843
Cash and cash equivalents at 31 March		1,526,028	1,522,541

All of the cash flows are derived from continuing operations during the above two periods.

Hannah's Willberry Wonder Pony Charity

Notes to the Financial Statements

Year Ended 31 March 2021

1 Charity status

The charity is a charity limited by guarantee and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation
Hannah's Willberry Wonder Pony Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern
The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing group accounts
The charity has taken advantage of the exemption in section 398 of the Companies Act 2006 from the requirement to prepare consolidated financial statements, on the grounds that it is a small sized group.

Income and endowments
All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured. Donations received through third party organisations such as Just Giving are shown net of any fees charged by these organisations.

Expenditure
All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grants

Grants are recognised at the amount payable when the intention to make a grant has been communicated to the recipient and the conditions of the grant have been met.

Governance costs
These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees's meetings and reimbursed expenses.

Taxation
The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Fixed asset investments
Investments in subsidiaries are stated at historical cost less provision for any diminution in value.

Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure
Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

3 Income from donations and legacies

	Unrestricted funds		
	General	Total 2021	Total 2020
	£	£	£
Donations and legacies;			
General donations	76,716	76,716	148,022
Donation from trading subsidiary	14,680	14,680	35,311
	91,396	91,396	183,333

4 Investment income

	Unrestricted funds		
	General	Total 2021	Total 2020
	£	£	£
Interest receivable and similar income;			
Interest receivable on bank deposits	5,503	5,503	7,497

5 Expenditure on charitable activities

	Note	Unrestricted funds		
		General	Total 2021	Total 2020
		£	£	£
Grant funding of activities		111,648	111,648	105,424
Allocated support costs	6	1,782	1,782	3,162
Governance costs	6	3,553	3,553	3,463
		116,983	116,983	112,049

£116,983 (2020 - £112,409) of the above expenditure was attributable to unrestricted funds and £Nil (2020 - £Nil) to restricted funds.

6 Analysis of governance and support costs

Charitable activities expenditure

	Unrestricted funds		
	General	Total 2021	Total 2020
	£	£	£
Office expenses	1,156	1,156	1,359
Insurance	542	542	528
Legal and professional fees	35	35	1,142
Printing, postage and stationary	49	49	133
Governance costs	3,553	3,553	3,463
	5,335	5,335	6,625

Governance costs

	Unrestricted funds		
	General	Total 2021	Total 2020
	£	£	£
Independent examiner fees			
Examination of the financial statements	2,250	2,250	2,350
Other fees paid to examiners	1,303	1,303	1,113
	3,553	3,553	3,463

7 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses from the charity during the year.

8 Independent examiner's remuneration

	2021 £	2020 £
Examination of the financial statements	2,250	2,350
Other fees to examiners		
All other services	1,303	1,113

9 Fixed asset investments

	2021 £	2020 £
Shares in group undertakings and participating interests	1	1

Details of undertakings

Details of the investments in which the charity holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking	Country of incorporation	Holding	Proportion of voting rights and shares held	Principal activity
Subsidiary undertakings				
The Willberry Wonder Pony Trading Company Limited	England and Wales	Ordinary	100%	Sale of merchandise and soft toys branded with Hannah's Willberry Wonder Pony

Subsidiaries

The trading subsidiary company donates its profits to the charity. For the period 1 April 2020 to 31 March 2021, the subsidiary's turnover was £31,298 (2020 - £71,871) and total expenditure was £31,298 (2020 - £71,871).

10 Debtors

	2021	2020
	£	£
Due from group undertakings	21,680	35,311

11 Creditors: amounts falling due within one year

	2021	2020
	£	£
Accruals	12,940	3,000

12 Funds

	Balance at 1 April 2020	Incoming resources	Resources expended	Balance at 31 March 2021
	£	£	£	£
Unrestricted funds				
General	1,554,853	96,899	(116,983)	1,534,769

	Balance at 1 April 2019	Incoming resources	Resources expended	Balance at 31 March 2020
	£	£	£	£
Unrestricted funds				
General	1,476,072	190,830	(112,049)	1,554,853

13 Analysis of net assets between funds

	Unrestricted funds General £	Total funds £
Fixed asset investments	1	1
Current assets	1,547,708	1,547,708
Current liabilities	(12,940)	(12,940)
Total net assets	1,534,769	1,534,769

14 Related party transactions

The charity has taken advantage of the exemption in Financial Reporting Standards 102 chapter 33 "Related Party Disclosure" and has not disclosed transactions with wholly owned group untertakings.

Donations made by the trustees without any conditions attached totalled £2,100 (2020 - £50) for the year.